Infectious pancreatic necrosis virus (IPNV) vaccine compositions

ABSTRACT

Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent applicationSer. No. 13/982,714, filed Jul. 30, 2013 which is a National PhaseApplication of PCT/US2013/049453 filed Jul. 5, 2013, which claims thebenefit of U.S. Provisional Application No. 61/668,314, filed Jul. 5,2012, each of which are hereby incorporated herein by reference in theirentirety.

BACKGROUND

Infectious bursal disease (also known as IBD, Gumboro Disease,Infectious Bursitis and Infectious Avian Nephrosis) is a highlycontagious disease of young chickens caused by infectious bursal diseasevirus (IBDV), characterized by immunosuppression and mortality generallyat 3 to 6 weeks of age. It is economically important to the poultryindustry worldwide due to increased susceptibility to other diseases andnegative interference with effective vaccination. In recent years, veryvirulent strains of IBDV (vvIBDV), causing severe mortality in chickens,have emerged in Europe, Latin America, South-East Asia, Africa and theMiddle East. Infection is via the oro-fecal route, with affected birdsexcreting high levels of the virus for approximately 2 weeks afterinfection.

IBDV is a double stranded RNA virus that has a bi-segmented genome andbelongs to the genus Avibimavirus of family Birnaviridae. There are twodistinct serotypes of the virus, but only serotype 1 viruses causedisease in poultry. At least six antigenic subtypes of IBDV serotype 1have been identified by in vitro cross-neutralization assay. Virusesbelonging to one of these antigenic subtypes are commonly known asvariants, which were reported to break through high levels of maternalantibodies in commercial flocks, and cause immune suppression.

The IBDV genome consists of two segments, A and B, which are enclosedwithin a nonenveloped icosahedral capsid. The genome segment B (2.9 kb)encodes VP1, the putative viral RNA polymerase. The larger segment A(3.2 kb) encodes viral proteins VP2, VP3, VP4, and VP5. Among them, VP2protein contains important neutralizing antigenic sites and elicits aprotective immune response and most of the amino acid (AA) changesbetween antigenically different IBDVs are clustered in the hypervariableregion of VP2. Thus, this hypervariable region of VP2 has been thetarget for the molecular techniques applied for IBDV detection andstrain variation studies.

The IBDV capsid protein exhibits structural domains that show homologyto those of the capsid proteins of some positive-sense single-strandedRNA viruses, such as the nodaviruses and tetraviruses, as well as theT=13 capsid shell protein of the Reoviridae. The T=13 shell of the IBDVcapsid is formed by trimers of VP2, a protein generated by removal ofthe C-terminal domain from its precursor, pVP2. The trimming of pVP2 isperformed on immature particles as part of the maturation process. Theother major structural protein, VP3, is a multifunctional componentlying under the T=13 shell that influences the inherent structuralpolymorphism of pVP2. The virus-encoded RNA-dependent RNA polymerase,VP1, is incorporated into the capsid through its association with VP3.VP3 also interacts extensively with the viral dsRNA genome.

Clinical disease is associated to bird age with the greatest bursalmass, which occurs between 3 and 6 weeks of age. The greatest bursalmass is mostly a result of a large population of maturing IgM-bearingB-lymphocytes (lymphoblasts), the main target of infection. Young birdsat around two to eight weeks of age that have a highly active bursa ofFabricius are more susceptible to disease. Birds over eight weeks aremore resistant to challenge and typically will not show clinical signsunless infected by highly virulent strains.

The poultry vaccine industry currently makes inactivated IBDV vaccinesfor administration to breeder chickens. Vaccinating parent breederflocks produces maternal immunity in the chicks and protects them duringthe first few weeks of life from infectious bursal disease (IBD). Inmany cases, the vaccines for IBD are prepared in young chicks ratherthan eggs or cell culture because the quality and quantity of theantigen is considered to be superior. This is an expensive and timeconsuming process. Furthermore, animal use issues have increased therisk of losing this source of high quality IBDV antigens. Using antigensproduced in eggs or cell culture could reduce the potency and efficacyof these vaccines and thus increase IBD related morbidity, mortality andthe cost of poultry meat and egg production.

Therefore, what is needed in the art are safe and effective vaccinesthat can be practically produced to prevent IBDV.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows IBDV pVP2 and VP3 clones excised from pGEM-T Easy vectorusing EcoRI. Lane M contains a molecular DNA ladder, lanes 1-5 containpVP2 clones, lanes 6-9 contain VP3 clones, lane 10 contains a negative(no insert) control and lane 11 contains an un-cut negative control.

FIG. 2 shows purified pVP2 and VP3 inserts from the pGEM-T Easy vector.

FIG. 3(A) shows pVP2 clones excised from pVL1393 using EcoRI. (B) VP3clones excised from pVL1393 using EcoRI.

FIG. 4 shows virus-like particles (VLPs) prepared in Sf9 cell culturesinfected with recombinant Baculoviruses. The pVP2 from the variantUSA08MD34p or classic Mo195 IBDV strains were co-expressed withUSA08MD34p-VP3. The mosaic VLPs contained pVP2 from the variant andclassic viruses. The horizontal bar on the bottom right of each electronmicrograph represents 200 nm.

FIG. 5 shows virus-like particles (VLPs) for infectious pancreaticnecrosis virus (IPNV) prepared in Sf9 cell cultures infected withrecombinant baculoviruses. The pVP2 from Genogroup 1 strains (eitherIPNV2 or IPNV10) were co-expressed with IPNV10 VP3 to give the VLPs. Thehorizontal bar on the bottom right of each electron micrographrepresents 200 nm.

DETAILED DESCRIPTION OF THE INVENTION

Before the present compounds, compositions, articles, devices, and/ormethods are disclosed and described, it is to be understood that theaspects described below are not limited to specific synthetic methods orspecific administration methods, as such may, of course, vary. It isalso to be understood that the terminology used herein is for thepurpose of describing particular aspects only and is not intended to belimiting.

It must be noted that, as used in the specification and the appendedclaims, the singular forms “a,” “an” and “the” include plural referentsunless the context clearly dictates otherwise.

“Optional” or “optionally” means that the subsequently described eventor circumstance can or cannot occur, and that the description includesinstances where the event or circumstance occurs and instances where itdoes not. For example, the phrase “optionally the composition cancomprise a combination” means that the composition may comprise acombination of different molecules or may not include a combination suchthat the description includes both the combination and the absence ofthe combination (i.e., individual members of the combination).

Ranges can be expressed herein as from “about” one particular value,and/or to “about” another particular value. When such a range isexpressed, another embodiment includes from the one particular valueand/or to the other particular value. Similarly, when values areexpressed as approximations, by use of the antecedent “about,” it willbe understood that the particular value forms another embodiment. Itwill be further understood that the endpoints of each of the ranges aresignificant both in relation to the other endpoint, and independently ofthe other endpoint. It is also understood that there are a number ofvalues disclosed herein, and that each value is also herein disclosed as“about” that particular value in addition to the value itself. Forexample, if the value “10” is disclosed, then “about 10” is alsodisclosed. It is also understood that when a value is disclosed that is“less than or equal to” the value, “greater than or equal to the value”and possible ranges between values are also disclosed, as appropriatelyunderstood by the skilled artisan. For example, if the value “10” isdisclosed then “less than or equal to 10” as well as “greater than orequal to 10” is also disclosed. It is also understood that throughoutthe application, data is provided in a number of different formats, andthat this data represents endpoints and starting points, and ranges forany combination of the data points. For example, if a particular datapoint “10” and a particular data point “15” are disclosed, it isunderstood that greater than, greater than or equal to, less than, lessthan or equal to, and equal to 10 and 15 are considered disclosed aswell as between 10 and 15.

By “probe,” “primer,” or oligonucleotide is meant a single-stranded DNAor RNA molecule of defined sequence that can base-pair to a second DNAor RNA molecule that contains a complementary sequence (the “target”).The stability of the resulting hybrid depends upon the extent of thebase-pairing that occurs. The extent of base-pairing is affected byparameters such as the degree of complementarity between the probe andtarget molecules and the degree of stringency of the hybridizationconditions. The degree of hybridization stringency is affected byparameters such as temperature, salt concentration, and theconcentration of organic molecules such as formamide, and is determinedby methods known to one skilled in the art. Probes or primers specificfor a nucleic acid (for example, genes and/or mRNAs) have at least80%-90% sequence complementarity, preferably at least 91%-95% sequencecomplementarity, more preferably at least 96%-99% sequencecomplementarity, and most preferably 100% sequence complementarity tothe region of the nucleic acid to which they hybridize. Probes, primers,and oligonucleotides may be detectably-labeled, either radioactively, ornon-radioactively, by methods well-known to those skilled in the art.Probes, primers, and oligonucleotides are used for methods involvingnucleic acid hybridization, such as: nucleic acid sequencing, reversetranscription and/or nucleic acid amplification by the polymerase chainreaction, single stranded conformational polymorphism (SSCP) analysis,restriction fragment polymorphism (RFLP) analysis, Southernhybridization, Northern hybridization, in situ hybridization,electrophoretic mobility shift assay (EMSA).

By “specifically hybridizes” is meant that a probe, primer, oroligonucleotide recognizes and physically interacts (that is,base-pairs) with a substantially complementary nucleic acid (forexample, a c-met nucleic acid) under high stringency conditions, anddoes not substantially base pair with other nucleic acids.

By “high stringency conditions” is meant conditions that allowhybridization comparable with that resulting from the use of a DNA probeof at least 40 nucleotides in length, in a buffer containing 0.5 MNaHPO4, pH 7.2, 7% SDS, 1 mM EDTA, and 1% BSA (Fraction V), at atemperature of 65° C., or a buffer containing 48% formamide, 4.8×SSC,0.2 M Tris-Cl, pH 7.6, 1×Denhardt's solution, 10% dextran sulfate, and0.1% SDS, at a temperature of 42° C. Other conditions for highstringency hybridization, such as for PCR, Northern, Southern, or insitu hybridization, DNA sequencing, etc., are well-known by thoseskilled in the art of molecular biology. (See, for example, F. Ausubelet al., Current Protocols in Molecular Biology, John Wiley & Sons, NewYork, N.Y., 1998).

Compositions

Disclosed are the components to be used to prepare the disclosedcompositions as well as the compositions themselves to be used withinthe methods disclosed herein. These and other materials are disclosedherein, and it is understood that when combinations, subsets,interactions, groups, etc. of these materials are disclosed that whilespecific reference of each various individual and collectivecombinations and permutation of these compounds may not be explicitlydisclosed, each is specifically contemplated and described herein. Forexample, if a particular VP2, VP3, or virus like particle (VLP) isdisclosed and discussed and a number of modifications that can be madeto a number of molecules including the VP2, VP3, or VLP are discussed,specifically contemplated is each and every combination and permutationof cancer gene or cooperation response gene and the modifications thatare possible unless specifically indicated to the contrary. Thus, if aclass of molecules A, B, and C are disclosed as well as a class ofmolecules D, E, and F and an example of a combination molecule, A-D isdisclosed, then even if each is not individually recited each isindividually and collectively contemplated meaning combinations, A-E,A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed.Likewise, any subset or combination of these is also disclosed. Thus,for example, the sub-group of A-E, B-F, and C-E would be considereddisclosed. This concept applies to all aspects of this applicationincluding, but not limited to, steps in methods of making and using thedisclosed compositions. Thus, if there are a variety of additional stepsthat can be performed it is understood that each of these additionalsteps can be performed with any specific embodiment or combination ofembodiments of the disclosed methods.

The genome of IBDV consists of two segments of double-stranded RNA(Dobos 1979). The smaller genome segment encodes the RNA-dependent RNApolymerase, VP1 (von Einem 2004). The larger genome segment encodes apolyprotein that is self-cleaved by the viral encoded protease VP4(Birghan 2000) to yield pVP2, VP3 and VP4 (Kibenge 1988). The pVP2protein is further cleaved multiple times at the COOH terminus to yieldthe mature capsid protein VP2 (Galloux 2007). Trimers of the VP2 proteinform a structure containing a base (B), shell (S) and projection (P)domain (Coulibaly 2010). The surface of the IBDV capsid is a singleprotein layer made up of 260 VP2 trimers and beneath this layer are atleast 200 trimers of the VP3 protein (Coulibaly 2005). During viralreplication, capsid formation may be initiated by a VP1-VP3 complexwhich interacts with VP2 trimers (Caston 2001; Moraver 2003; Lombardo1999). However, in the absence of VP1, the molecular co-expression ofpVP2 and VP3 also produced the correct capsid structure (Martinez 2000).The COOH terminal domain of pVP2 was essential for the assembly of theproteins into these virus-like particles (VLPs) (Ona 2004)

The antigenic variability among IBDV strains has been recognized fordecades. It is determined by amino acids that constitute VP2 (Heine1991; Eterradossi 1997; Eterradossi 1998). Specifically, amino acids inthe P domain of VP2 are critical for the binding of neutralizingmonoclonal antibodies (Letzel 2007). Neutralizing antibody escape mutantviruses had substitution mutations in the PBC, PDE and PHI domains(Vakharia 1994; Letzel 2007). Amino acid substitution mutations in thePBC and PDE domains also contributed to antigenic drift among IBDVstrains (Schnitzler 1993).

As disclosed in Example 1, nucleotide sequences that encode the pVP2proteins from a variant IBDV strain designated USA08MD34p and a classicIBDV strain designated Mo195 were produced using RT-PCR and cloned intoa pGEM-T Easy vector. A nucleotide sequence that encodes the VP3 proteinwas also produced from the USA08MD34p viral genome using RT-PCR andcloned into a pGEM-T Easy vector. The VP3 and pVP2 clones were insertedinto the pVL1393 Baculovirus transfer vector and sequenced to confirmtheir orientation to the promoter and to insure they containeduninterrupted open-reading-frames. Recombinant Baculoviruses wereconstructed by transfection in Sf9 cells. Three recombinantBaculoviruses were produced and contained the USA08MD34p-VP3,USA08MD34p-pVP2 or Mo195-pVP2 genomic sequences.

Virus-like particles (VLPs) were observed using transmission electronmicroscopy when the USA08MD34p-VP3 Baculovirus was co-inoculated intoSf9 cells with either of the pVP2 constructs. VLPs were also observedwhen the USA08MD34p-pVP2 and Mo195-pVP2 were co-expressed withUSA08MD34p-VP3. These mosaic VLPs contained both classic and variantpVP2s. The USA08MD34p, Mo195 and mosaic VLPs were used to vaccinatechickens. They induced an IBDV specific antibody response that wasdetected by ELISA and virus-neutralizing antibodies were detected invitro. Chickens vaccinated with the mosaic VLPs were protected from avirulent variant IBDV strain (V1) and a virulent classic IBDV strain(STC). The results indicate the mosaic VLPs maintained the antigenicintegrity of the variant and classic viruses and have the potential toserve as a multivalent vaccine for use in breeder flocks.

VP2

Disclosed herein is a polyvalent VP2. By “VP2 of IBDV” and “VP3 of IBDV”is meant the full-length or substantially full-length IBDV viralprotein, a fragment thereof, a fusion, or a viral protein with internaldeletions. VP2 and VP3 can have the ability to form VLPs underconditions that favor VLP formation. Thus, VP2 can include pVP2/VPX, andVP2 wherein a portion of the C-terminal domain sufficient to form VLPsexists.

The polyvalent VP2 can be a trimer comprised of three VP2 monomers, ortrimer forming fragments thereof. The term “polyvalent” refers to theVP2 trimer which is comprised of at least one VP2 monomer that isantigenically distinct from at least one other VP2 monomer in the VP2trimer.

By “antigenically distinct” is meant that the monomers individually oras part of a trimer elicits a humoral/antibody response such that themonomers or trimers can be distinguished from other monomers or trimmerssuing antibodies. An “antigen” or “antigenic” refers to a moleculecontaining one or more epitopes (either linear, conformational or both)that will stimulate a host's immune-system to make a humoral and/orcellular antigen-specific response.

“Immunogen” refers to a molecule that is able to provoke a humoraland/or cell-mediated immune response. Normally, a B-cell epitope willinclude at least about 5 amino acids but can be as small as 3-4 aminoacids. A T-cell epitope, such as a CTL epitope, will include at leastabout 7-9 amino acids, and a helper T-cell epitope at least about 12-20amino acids. Normally, an epitope will include between about 7 and 15amino acids, such as, 9, 10, 12 or 15 amino acids. Immunogens include,but is not limited to, polypeptides which include modifications, such asdeletions, additions and substitutions (generally conservative innature) as compared to a native sequence, so long as the proteinmaintains the ability to elicit an immunological response, as definedherein. Such modifications may be deliberate, as through site-directedmutagenesis, or may be accidental, such as through mutations of hostswhich produce the antigens.

An “immunological response” or “immune response” to an antigen,immunogen or composition is the development in a subject of a humoraland/or a cellular immune response to an antigen present in thecomposition of interest.

It is understood herein that an “immune response” refers to anyinflammatory, humoral, or cell-mediated response that occurs for thepurpose of eliminating an antigen. Such responses can include, but arenot limited to, antibody production, cytokine secretion, complementactivity, and cytolytic activity. In one embodiment, the immune responseis an antibody response.

A “humoral immune response” refers to an immune response mediated byantibody molecules, whereas a “cellular immune response” is one mediatedby T-lymphocytes and/or other white blood cells. A “cellular immuneresponse” can also refers to the production of cytokines, chemokines andother such molecules produced by activated T-cells and/or other whiteblood cells, including those derived from CD4+ and CD8+ T-cells. Hence,an immunological response may include one or more of the followingeffects: the production of antibodies by B-cells; and/or the activationof T-cells directed specifically to an antigen or antigens present inthe composition or vaccine of interest. These responses may serve toneutralize infectivity, and/or mediate antibody-complement, or antibodydependent cell cytotoxicity (ADCC) to provide protection to an immunizedhost. Such responses can be determined using standard immunoassays andneutralization assays, well known in the art.

An “immunogenic composition” refers to a composition that comprises anantigenic molecule where administration of the composition to a subjectresults in the development in the subject of a humoral and/or a cellularimmune response to the antigenic molecule of interest.

The VP2 monomers, or trimer forming fragments thereof, can be selectedfrom known IBDV strains, for example as provided herein, includingnatural segment A and B reassortments, variant strains, classic strains,very virulent strains, or from future discovered strains of IBDV.Examples of vvIBDV include but are not limited to UK661 (AJ878898), rA(GQ221682) and rB (GQ221683). Examples of variant viruses include butare not limited to Del-E (AJ878905), Del-A (Y1459), GLS (AJ878906), V1(AF281235), GER (AF281228) and USA02CA viruses (HQ441143-HQ441158).Examples of classic viruses include but are not limited to D78 (Y14962),Bursine (AJ878894), F52/70 (Y14958), Cu-1 ((AJ878886), V877 (AJ878882)and S706 (AJ878891). Examples of reassorted viruses include but are notlimited to IBDV strain 02015.1 (GenBank accession numbers AJ879932 andAJ88090), CA-D495 (HQ441142), CA-K785 (HQ441143), and GX (AJ878907).Other examples of strains that could be used as the VP2 of IBDV include,but are not limited to UPM97/61 (AF247006), UPM94/273 (AF527039), OKYM(D49706), UK661 (X92760), IBDKS (L42284), D6948 (AF240686), BD3/99(AF362776), Tasik94 (AF322444), Chinju (AF508176), HK46 (AF092943), SH95(AF13474), Gx (AY 444873), SDH1 (AY323952) and T09 (AY099456), D78(AF499929), Cu-1M (AF362771), P2 (X84034), CT (AJ310185), CEF94(AF194428), PBG-98 (D00868), JD1 (AF321055), HZ-2 (AF321054), TADGumboro (CAI47764), Delvax, Gumboro LZD, IBDVAC, 89163, Farager 52/70and Edgar (AF462026).

Any combination of VP2s can be utilized to form the trivalent VP2. Thus,provided herein are polyvalent VP2s comprising variant and/or classicand/or very virulent monomers. The VP2 monomer can comprise theidentical amino acid sequences of a naturally occurring IBDV strain,modified amino acids not occurring naturally, fusions, or antigenicfragments thereof. Amino acid and nucleic acid sequences of VP2 monomerscan be one or more of the sequences identified herein as SEQ ID Nos.herein for VP2 and/or one or more of the sequences described in Genbank,such as Accession Number AAV68391. For example, the polyvalent VP2 cancomprise a VP2 monomer of IBDV variant strain USA08MD34p, or a VP2monomer of IBDV classic strain Mo195. In another example, the polyvalentVP2 can comprise a VP2 monomer of IBDV variant strain USA08MD34p, or aVP2 monomer of IBDV classic strain Mo195 or a VP2 monomer from an IBDVstrain which is not IBDV variant strain USA08MD34p and is not IBDVclassic strain Mo195. The polyvalent VP2 can also comprise two VP2monomers from IBDV variant strain USA08MD34p and one VP2 monomer fromIBDV classic strain Mo195. In yet another example, the polyvalent VP2can comprise one VP2 monomer from IBDV variant strain USA08MD34p and twoVP2 monomers from IBDV classic strain Mo195. The polyvalent VP2 can alsocomprise two VP2 monomers of one IBDV and one an antigenically distinctIBDV monomer.

Thus, in one aspect, it is understood, that the polyvalent VP2 of IBDVcan have the following formula: R1-R2-R3, wherein R1-R2-R3 are each VP2monomers selected from the group consisting of IBDV strain USA08MD34p,classic strain Mo195, UPM97/61 (AF247006), UPM94/273 (AF527039), OKYM(D49706), UK661 (X92760), IBDKS (L42284), D6948 (AF240686), BD3/99(AF362776), Tasik94 (AF322444), Chinju (AF508176), HK46 (AF092943), SH95(AF13474), Gx (AY 444873), SDH1 (AY323952) and T09 (AY099456), D78(AF499929), Cu-1M (AF362771), P2 (X84034), CT (AJ310185), CEF94(AF194428), PBG-98 (D00868), JD1 (AF321055), HZ-2 (AF321054), TADGumboro, Delvax, Gumboro LZD, IBDVAC, 89163, Farager 52/70 and Edgar(AF462026); vvIBDV including but not limited to UK661 (AJ878898), rA(GQ221682) and rB (GQ221683); variant viruses including but not limitedto Del-E (AJ878905), Del-A (Y1459), GLS (AJ878906), V1 (AF281235), GER(AF281228) and USA02CA viruses (HQ441143-HQ441158); classic virusesincluding but not limited to D78 (Y14962), Bursine (AJ878894), F52/70(Y14958), Cu-1 (AJ878886), V877 (AJ878882), and S706 (AJ878891); andreassorted viruses including but not limited to CA-D495 (HQ441142),CA-K785 (HQ441143), IBDV strain 02015.1 (GenBank accession numbersAJ879932 and AJ88090), and GX (AJ878907). In one aspect, for example, atleast one of R1, R2 and R3 is an antigenically distinct monomer from oneor both of the other two monomers. In another aspect, at least one ofR1, R2 and R3 is a VP2 monomer from a different strain of IBDV than theother monomers. Thus, provided herein are polyvalent VP2s comprising R1,R2 and R3 comprised of variant and/or classic and/or very virulentstrain monomers. In yet another example, at least one of R1, R2 and R3is a VP2 monomer of variant strain USA08MD34p and is an antigenicallydistinct monomer from at least one other monomer. In another example, atleast one of R1, R2 and R3 is a VP2 monomer of IBDV classic strain Mo195and is an antigenically distinct monomer from at least one othermonomer. In another embodiment, at least one monomer is antigenicallydistinct from both other monomers.

Virus-Like Particles (VLPs)

In one aspect, disclosed herein are mosaic virus like particles (VLPs)comprising aVP2 as disclosed herein. As used herein, the terms“virus-like particle” or “VLP” refer to a nonreplicating, viral shell.VLPs are generally composed of one or more viral proteins, such as, butnot limited to VP2s in the combinations disclosed herein, for example acombination of VP2 and VP3s. VLPs can form spontaneously uponrecombinant expression of the protein in an appropriate expressionsystem. VLPs, when administered to an animal, can be immunogenic andthus can cause a protective or therapeutic immune response in theanimal. Methods for producing VLPs are generally known in the art anddiscussed more fully below. The presence of VLPs following recombinantexpression of viral proteins can be detected using conventionaltechniques known in the art, such as by electron microscopy, biophysicalcharacterization, and the like. See, e.g., Baker et al., Biophys. J.(1991) 60:1445-1456; Hagensee et al., J. Virol. (1994) 68:4503-4505. Forexample, VLPs can be isolated by density gradient centrifugation and/oridentified by characteristic density banding. Alternatively,cryoelectron microscopy can be performed on vitrified aqueous samples ofthe VLP preparation in question, and images recorded under appropriateexposure conditions.

Also disclosed are mosaic virus like particles (VLPs). By “mosaic” ismeant that the VLP comprises at least one VP2 trimer that is antigeniclydistinct from at least one other VP2 trimer in the VLP. thus, forexample disclosed herein are mosaic VLPs comprising a VP2 trimer from adifferent strain of IBDV than at least one VP2 trimers. The mosaic VLPcan generate a polyvalent immune response. The VLP may can contain amultivalent VP2 and/or a monovalent VP2. A “monovalent VP2” means a VP2trimer comprised of the same or substantially the same VP2 monomer. Forexample, the mosaic VLP can comprise two or more monovalent VP2 trimersand/or one or more polyvalent VP2 trimers. Mosaic VLPs comprisingmixtures of monovalent and polyvalent VP2 trimers or exclusivelymonovalent or exclusively polyvalent VLP trimers are also disclosedherein.

Also disclosed herein are antigenically distinct trimers. Antigenicallydistinct trimers can be derived from or represented by different strainsof IBDV, for example as provided herein. The VP2 trimers, or antigenicfragments thereof, whether polyvalent or monovalent, can be selectedfrom known IBDV strains, such as those disclosed herein, or fromadditional strains of IBDV. The VP2 trimer can be selected for examplefrom variant, classic, and very virulent strains. Thus, provided hereinare mosaic VLPs comprised of VP2s from variant and/or classic and/orvery virulent monomers. The VLP VP2 trimer can be polyvalent comprisingtwo or more antigenically distinct or variant monomers and/or monomershaving the identical amino acid sequences of a naturally occurring IBDVstrain (i.e., the VLP can simultaneously comprise polyvalent andmonovalent trimmers), can comprise modified amino acids not occurringnaturally, can comprise fusions, or can comprise antigenic fragmentsthereof.

The amino acid sequence of VP2 monomers making up the VP2 trimers in themosaic VLP can be one or more of the sequences identified herein as SEQID Nos. and/or one or more of the sequences described, for example, inGenbank Accession No. CAI47764. In another example, a polyvalent ormonovalent VP2 trimer in the VLP can comprise a VP2 monomer of IBDVvariant strain USA08MD34p, and/or a VP2 monomer of IBDV classic strainMo195. In another example, the polyvalent or monovalent VP2 can comprisea VP2 monomer of IBDV variant strain USA08MD34p, a VP2 monomer of IBDVclassic strain Mo195 and a VP2 monomer from an IBDV strain which is notIBDV variant strain USA08MD34p and is not IBDV classic strain Mo195.Examples of other strains that can be used as the VP2 of IBDV include,but are not limited to UPM97/61 (AF247006), UPM94/273 (AF527039), OKYM(D49706), UK661 (X92760), IBDKS (L42284), D6948 (AF240686), BD3/99(AF362776), Tasik94 (AF322444), Chinju (AF508176), HK46 (AF092943), SH95(AF13474), Gx (AY 444873), SDH1 (AY323952) and T09 (AY099456), D78(AF499929), Cu-1M (AF362771), P2 (X84034), CT (AJ310185), CEF94(AF194428), PBG-98 (D00868), JD1 (AF321055), HZ-2 (AF321054), TADGumboro, Delvax, Gumboro LZD, IBDVAC, 89163, Farager 52/70, and Edgar(AF462026). The VP2 monomers that make up the monovalent or polyvalentVP2 trimers, or fragments thereof, can be selected from known IBDVstrains, for example as provided herein, or from future discoveredstrains of IBDV. Any combination of monovalent or polyvalent VP2s can beutilized to form the VLP. In addition, examples of the polyvalent VP2trimers can, for example, comprise two VP2 monomers from IBDV variantstrain USA08MD34p and one VP2 monomer from IBDV classic strain Mo195. Inyet another example, the polyvalent VP2 trimer can comprise one VP2monomer IBDV variant strain USA08MD34p and two VP2 monomers from IBDVclassic strain Mo195. Likewise, the polyvalent VP2 trimer can, forexample, comprise two VP2 monomers of one IBDV monomer and one IBDV froman antigenically distinct monomer.

The VLP can further comprise a VP3 or a fragment thereof, or any otherprotein or polypeptide allowing the assembly of antigenic or immunogenicVP2 trimers as a VLP of the invention. The VLP can also comprise otherIBDV proteins such a VP1. Proteins from viruses having similarfunctionality to VP3 can also comprise the VLPs of this invention.

Antibodies

Disclosed herein are methods for the generation of antibodies thatspecifically recognize the mosaics and fragments of the VP2s and VLPsdisclosed herein. These antibodies, whether polyclonal, monoclonal,chimeric, or antibody fragments would recognize and target the mosaicsand fragments disclosed herein. Antibodies to any of the substances onthe list of mosaics can also be used as “passive vaccines” for thedirect immunotherapeutic targeting of IBDV of the corresponding VP2s orVLPs disclosed herein in vivo. It is understood that disclosed are anyantibody including monoclonal, polyclonal, or chimerized for example,binding any fragment of any of the compositions disclosed herein.

The antibodies provided herein are capable of neutralizing IBDV of otherclosely related species to IBDV. The provided antibodies can bedelivered directly, such as through needle injection, for example, totreat IBDV infections. The provided antibodies can be deliverednon-invasively, such as intranasally, for example. The antibodies canalso be encapsulated, for example into lipsomes, microspheres, or othertransfection enhancement agents, for improved delivery into the cells tomaximize the treatment efficiency. The gene sequences encoding theprovided antibodies, or their fragments such as Fab fragments, canfurther be cloned into genetic vectors, such as plasmid or viralvectors, for example, and delivered into the hosts for endogenouseexpression of the antibodies for treatment of IBDV.

As used herein, the term “antibody” encompasses, but is not limited to,whole immunoglobulin (i.e., an intact antibody) of any class. Nativeantibodies are usually heterotetrameric glycoproteins, composed of twoidentical light (L) chains and two identical heavy (H) chains.Typically, each light chain is linked to a heavy chain by one covalentdisulfide bond, while the number of disulfide linkages varies betweenthe heavy chains of different immunoglobulin isotypes. Each heavy andlight chain also has regularly spaced intrachain disulfide bridges. Eachheavy chain has at one end a variable domain (V(H)) followed by a numberof constant domains. Each light chain has a variable domain at one end(V(L)) and a constant domain at its other end; the constant domain ofthe light chain is aligned with the first constant domain of the heavychain, and the light chain variable domain is aligned with the variabledomain of the heavy chain. Particular amino acid residues are believedto form an interface between the light and heavy chain variable domains.The light chains of antibodies from any vertebrate species can beassigned to one of two clearly distinct types, called kappa (k) andlambda (l), based on the amino acid sequences of their constant domains.Depending on the amino acid sequence of the constant domain of theirheavy chains, immunoglobulins can be assigned to different classes.

The term “variable” is used herein to describe certain portions of thevariable domains that differ in sequence among antibodies and are usedin the binding and specificity of each particular antibody for itsparticular antigen. However, the variability is not usually evenlydistributed through the variable domains of antibodies. It is typicallyconcentrated in three segments called complementarity determiningregions (CDRs) or hypervariable regions both in the light chain and theheavy chain variable domains. The more highly conserved portions of thevariable domains are called the framework (FR). The variable domains ofnative heavy and light chains each comprise four FR regions, largelyadopting a b-sheet configuration, connected by three CDRs, which formloops connecting, and in some cases forming part of, the b-sheetstructure. The CDRs in each chain are held together in close proximityby the FR regions and, with the CDRs from the other chain, contribute tothe formation of the antigen binding site of antibodies (see Kabat E. A.et al., “Sequences of Proteins of Immunological Interest,” NationalInstitutes of Health, Bethesda, Md. (1987)). The constant domains arenot involved directly in binding an antibody to an antigen, but exhibitvarious effector functions, such as participation of the antibody inantibody-dependent cellular toxicity.

As used herein, the term “antibody or fragments thereof” encompasseschimeric antibodies and hybrid antibodies, with dual or multiple antigenor epitope specificities, and fragments, such as Fv, sFv, F(ab′)2, Fab′,Fab and the like, including hybrid fragments. Thus, fragments of theantibodies that retain the ability to bind their specific antigens areprovided. For example, fragments of antibodies which maintain EFnbinding activity are included within the meaning of the term “antibodyor fragment thereof” Such antibodies and fragments can be made bytechniques known in the art and can be screened for specificity andactivity using general methods for producing antibodies and screeningantibodies for specificity and activity (See Harlow and Lane.Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, NewYork, (1988)).

Also included within the meaning of “antibody or fragments thereof” areconjugates of antibody fragments and antigen binding proteins (singlechain antibodies) as described, for example, in U.S. Pat. No. 4,704,692,the contents of which are hereby incorporated by reference.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a substantially homogeneous population of antibodies,i.e., the individual antibodies within the population are identicalexcept for possible naturally occurring mutations that may be present ina small subset of the antibody molecules. The monoclonal antibodiesherein specifically include “chimeric” antibodies in which a portion ofthe heavy and/or light chain is identical with or homologous tocorresponding sequences in antibodies derived from a particular speciesor belonging to a particular antibody class or subclass, while theremainder of the chain(s) is identical with or homologous tocorresponding sequences in antibodies derived from another species orbelonging to another antibody class or subclass, as well as fragments ofsuch antibodies, as long as they exhibit the desired antagonisticactivity.

The disclosed monoclonal antibodies can be made using any procedurewhich produces monoclonal antibodies. For example, disclosed monoclonalantibodies can be prepared using hybridoma methods, such as thosedescribed by Kohler and Milstein, Nature, 256:495 (1975). In a hybridomamethod, a mouse or other appropriate host animal is typically immunizedwith an immunizing agent to elicit lymphocytes that produce or arecapable of producing antibodies that will specifically bind to theimmunizing agent. Alternatively, the lymphocytes may be immunized invitro.

The monoclonal antibodies may also be made by recombinant DNA methods,such as those described in U.S. Pat. No. 4,816,567 (Cabilly et al.). DNAencoding the disclosed monoclonal antibodies can be readily isolated andsequenced using conventional procedures (e.g., by using oligonucleotideprobes that are capable of binding specifically to genes encoding theheavy and light chains of murine antibodies). Libraries of antibodies oractive antibody fragments can also be generated and screened using phagedisplay techniques.

In vitro methods are also suitable for preparing monovalent antibodies.Digestion of antibodies to produce fragments thereof, particularly, Fabfragments, can be accomplished using routine techniques known in theart. For instance, digestion can be performed using papain. Examples ofpapain digestion are described in WO 94/29348 published Dec. 22, 1994and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typicallyproduces two identical antigen binding fragments, called Fab fragments,each with a single antigen binding site, and a residual Fc fragment.Pepsin treatment yields a fragment that has two antigen combining sitesand is still capable of cross-linking antigen.

The fragments, whether attached to other sequences or not, can alsoinclude insertions, deletions, substitutions, or other selectedmodifications of particular regions or specific amino acids residues,provided the activity of the antibody or antibody fragment is notsignificantly altered or impaired compared to the non-modified antibodyor antibody fragment. These modifications can provide for someadditional property, such as to remove/add amino acids capable ofdisulfide bonding, to increase its bio-longevity, to alter its secretorycharacteristics, etc. In any case, the antibody or antibody fragmentmust possess a bioactive property, such as specific binding to itscognate antigen. Functional or active regions of the antibody orantibody fragment may be identified by mutagenesis of a specific regionof the protein, followed by expression and testing of the expressedpolypeptide. Such methods are readily apparent to a skilled practitionerin the art and can include site-specific mutagenesis of the nucleic acidencoding the antibody or antibody fragment.

As used herein, the term “antibody” or “antibodies” can also refer to ahuman antibody and/or a humanized antibody. Many non-human antibodies(e.g., those derived from mice, rats, or rabbits) are naturallyantigenic in humans, and thus can give rise to undesirable immuneresponses when administered to humans. Therefore, the use of human orhumanized antibodies in the methods serves to lessen the chance that anantibody administered to a human will evoke an undesirable immuneresponse.

Human Antibodies

The disclosed human antibodies can be prepared using any technique.Examples of techniques for human monoclonal antibody production includethose described by Cole et al. Human antibodies (and fragments thereof)can also be produced using phage display libraries.

The disclosed human antibodies can also be obtained from transgenicanimals. For example, transgenic, mutant mice that are capable ofproducing a full repertoire of human antibodies, in response toimmunization. Specifically, the homozygous deletion of the antibodyheavy chain joining region (J(H)) gene in these chimeric and germ-linemutant mice results in complete inhibition of endogenous antibodyproduction, and the successful transfer of the human germ-line antibodygene array into such germ-line mutant mice results in the production ofhuman antibodies upon antigen challenge. Antibodies having the desiredactivity are selected using Env-CD4-co-receptor complexes as describedherein.

Humanized Antibodies

Antibody humanization techniques generally involve the use ofrecombinant DNA technology to manipulate the DNA sequence encoding oneor more polypeptide chains of an antibody molecule. Accordingly, ahumanized form of a non-human antibody (or a fragment thereof) is achimeric antibody or antibody chain (or a fragment thereof, such as anFv, Fab, Fab′, or other antigen-binding portion of an antibody) whichcontains a portion of an antigen binding site from a non-human (donor)antibody integrated into the framework of a human (recipient) antibody.

To generate a humanized antibody, residues from one or morecomplementarity determining regions (CDRs) of a recipient (human)antibody molecule are replaced by residues from one or more CDRs of adonor (non-human) antibody molecule that is known to have desiredantigen binding characteristics (e.g., a certain level of specificityand affinity for the target antigen). In some instances, Fv framework(FR) residues of the human antibody are replaced by correspondingnon-human residues. Humanized antibodies may also contain residues whichare found neither in the recipient antibody nor in the imported CDR orframework sequences. Generally, a humanized antibody has one or moreamino acid residues introduced into it from a source which is non-human.In practice, humanized antibodies are typically human antibodies inwhich some CDR residues and possibly some FR residues are substituted byresidues from analogous sites in rodent antibodies. Humanized antibodiesgenerally contain at least a portion of an antibody constant region(Fc), typically that of a human antibody

Disclosed herein are antigens expressed in baculovirus. The advantagesto this system include ease of generation, high levels of expression,and post-translational modifications that are highly similar to thoseseen in mammalian systems. The antigen is produced by inserting a genefragment in-frame between the signal sequence and the mature proteindomain of a nucleotide sequence.

Nucleic Acids and Cells

It is understood and herein contemplated that in one aspect the VP2,VP3, and/or VLPs are present in the disclosed compositions as nucleicacids. The phrase “nucleic acid” as used herein refers to a naturallyoccurring or synthetic oligonucleotide or polynucleotide, whether DNA orRNA or DNA-RNA hybrid, single-stranded or double-stranded, sense orantisense, which is capable of hybridization to a complementary nucleicacid by Watson-Crick base-pairing. Nucleic acids of the invention canalso include nucleotide analogs (e.g., BrdU), and non-phosphodiesterinternucleoside linkages (e.g., peptide nucleic acid (PNA) orthiodiester linkages). In particular, nucleic acids can include, withoutlimitation, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA or any combinationthereof

The nucleic acids, such as SEQ ID NOS 1-24, as described herein, can bemade using standard chemical synthesis methods or can be produced usingenzymatic methods or any other known method. Such methods can range fromstandard enzymatic digestion followed by nucleotide fragment isolation(see for example, Sambrook et al., Molecular Cloning: A LaboratoryManual, 3rd Edition (Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N.Y., 2001) Chapters 5, 6) to purely synthetic methods, forexample, by the cyanoethyl phosphoramidite method using a Milligen orBeckman System 1Plus DNA synthesizer. Synthetic methods useful formaking oligonucleotides are also described by Ikuta et al., Ann. Rev.Biochem. 53:323-356 (1984), (phosphotriester and phosphite-triestermethods), and Narang et al., Methods Enzymol., 65:610-620 (1980),(phosphotriester method). Protein nucleic acid molecules can be madeusing known methods such as those described by Nielsen et al.,Bioconjug. Chem. 5:3-7 (1994).

The compositions disclosed herein can be produced as described hereinand can be prepared using standard recombinant techniques.Polynucleotides encoding the VLP-forming protein(s) are introduced intoa host cell and, when the proteins are expressed in the cell, they canassemble into the VP2s or VLPs.

Polynucleotide sequences coding for proteins or polypeptides (structuraland/or antigen polypeptides, including modified antigenic polypeptides)that form and/or are incorporated into the VP2s and VLPs can be obtainedusing recombinant methods, such as by screening cDNA and genomiclibraries from cells expressing the gene, or by deriving the gene from avector known to include the same. For example, plasmids which containsequences that encode naturally occurring or altered cellular productsmay be obtained from a depository such as the A.T.C.C., or fromcommercial sources. Plasmids containing the nucleotide sequences ofinterest can be digested with appropriate restriction enzymes, and DNAfragments containing the nucleotide sequences can be inserted into agene transfer vector using standard molecular biology techniques.

Alternatively, cDNA sequences may be obtained from cells which expressor contain the sequences, using standard techniques, such as phenolextraction and PCR of cDNA or genomic DNA. See, e.g., Sambrook et al.,supra, for a description of techniques used to obtain and isolate DNA.Briefly, mRNA from a cell which expresses the gene of interest can bereverse transcribed with reverse transcriptase using oligo-dT or randomprimers. The single stranded cDNA may then be amplified by PCR (see U.S.Pat. Nos. 4,683,202, 4,683,195 and 4,800,159, see also PCR Technology:Principles and Applications for DNA Amplification, Erlich (ed.),Stockton Press, 1989)) using oligonucleotide primers complementary-tosequences on either side of desired sequences.

The nucleotide sequence of interest can also be produced synthetically,rather than cloned, using a DNA synthesizer (e.g., an Applied BiosystemsModel 392 DNA Synthesizer, available from ABI, Foster City, Calif.). Thenucleotide sequence can be designed with the appropriate codons for theexpression product desired. The complete sequence is assembled fromoverlapping oligonucleotides prepared by standard methods and assembledinto a complete coding sequence. See, e.g., Edge (1981) Nature 292:756;Nambair et al. (1984) Science 223:1299; Jay et al. (1984) J. Biol. Chem.259:6311.

Any of the proteins used in the VP2s and VLPs described herein may behybrid (or chimeric) proteins, referred to herein as mosaics. It will beapparent that all or parts of the polypeptides can be replaced withsequences from other viruses and/or sequences from other IBDV strains solong as the sequence does not prevent the formation of VP2 trimersand/or VLPs.

Preferably, the sequences employed to form the VP2s and VLPs disclosedherein can exhibit between about 60% to 80% (or any value therebetweenincluding 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%,73%, 74%, 75%, 76%, 77%, 78% and 79%) sequence identity to a naturallyoccurring IBDV polynucleotide sequence and more preferably the sequencesexhibit between about 80% and 100% (or any value therebetween including81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,95%, 96%, 97%, 98% and 99%) sequence identity to a naturally occurringpolynucleotide sequence.

Any of the sequences described herein may further include additionalsequences. For example, to further to enhance vaccine potency, hybridmolecules are expressed and incorporated into the sub-viral structure.These hybrid molecules are generated by linking for example, at the DNAlevel, the sequences coding for the VP2s or VP3s with sequences codingfor an adjuvant or immuno-regulatory moiety. The incorporation of one ormore polypeptide immunomodulatory polypeptides (e.g., adjuvantsdescribed herein) into the sequences described herein into the VP2s andVLPs can enhance potency and therefore reduces the amount of antigenrequired for stimulating a protective immune response. Alternatively, asdescribed below, one or more additional molecules (polypeptide or smallmolecules) may be included in the VP2s and VLPs after production of thecomposition from the sequences described herein.

These sub-viral structures do not contain infectious viral nucleic acidsand they are not infectious eliminating the need for chemicalinactivation. Absence of chemical treatment preserves native epitopesand protein conformations enhancing the immunogenic characteristics ofthe vaccine.

The sequences described herein can be operably linked to each other inany combination. For example, one or more sequences may be expressedfrom the same promoter and/or from different promoters. As describedbelow, sequences may be included on one or more vectors.

Expression Vectors

Once the constructs comprising the sequences encoding the polypeptide(s)desired to be incorporated into the VP2s and VLPs have been synthesized,they can be cloned into any suitable vector or replicon for expression.Numerous cloning vectors are known to those of skill in the art, and onehaving ordinary skill in the art can readily select appropriate vectorsand control elements for any given host cell type in view of theteachings of the present specification and information known in the artabout expression. See, generally, Ausubel et al, supra or Sambrook etal, supra.

Non-limiting examples of vectors that can be used to express sequencesthat assembly into VP2s and VLPs as described herein include viral-basedvectors (e.g., retrovirus, adenovirus, adeno-associated virus,lentivirus), baculovirus vectors (see Examples), plasmid vectors,non-viral vectors, mammalians vectors, mammalian artificial chromosomes(e.g., liposomes, particulate carriers, etc.) and combinations thereof.

The expression vector(s) typically contain(s) coding sequences andexpression control elements which allow expression of the coding regionsin a suitable host. The control elements generally include a promoter,translation initiation codon, and translation and transcriptiontermination sequences, and an insertion site for introducing the insertinto the vector. Translational control elements have been reviewed by M.Kozak (e.g., Kozak, M., Mamm. Genome 7(8):563-574, 1996; Kozak, M.,Biochimie 76(9):815-821, 1994; Kozak, M., J Cell Biol 108(2):229-241,1989; Kozak, M., and Shatkin, A. J., Methods Enzymol 60:360-375, 1979).

It will be apparent that one or more vectors may contain one or moresequences encoding proteins to be incorporated into the VP2s and VLPs.For example, a single vector may carry sequences encoding all theproteins found in the composition. Alternatively, multiple vectors maybe used (e.g., multiple constructs, each encoding a singlepolypeptide-encoding sequence or multiple constructs, each encoding oneor more polypeptide-encoding sequences). In embodiments in which asingle vector comprises multiple polypeptide-encoding sequences, thesequences may be operably linked to the same or differenttranscriptional control elements (e.g., promoters) within the samevector. Furthermore, vectors may contain additional gene expressioncontrolling sequences including chromatin opening elements which preventtransgene silencing and confer consistent, stable and high level of geneexpression, irrespective of the chromosomal integration site. These areDNA sequence motifs located in proximity of house-keeping genes, whichin the vectors create a transcriptionally active open chromatinenvironment around the integrated transgene, maximizing transcriptionand protein expression, irrespective of the position of the transgene inthe chromosome.

In addition, one or more sequences encoding non-IBDV proteins may beexpressed and incorporated into the VP2s and VLPs, including, but notlimited to, sequences comprising and/or encoding immunomodulatorymolecules (e.g., adjuvants described below), for example,immunomodulating oligonucleotides (e.g., CpGs), cytokines, detoxifiedbacterial toxins and the like.

Various modifications and variations can be made to the compounds,compositions and methods described herein. Other aspects of thecompounds, compositions and methods described herein will be apparentfrom consideration of the specification and practice of the compounds,compositions and methods disclosed herein. It is intended that thespecification and examples be considered as exemplary.

Peptides

By “particle-forming polypeptide” derived from a particular viralprotein is meant a full-length viral protein or a fragment thereof, afusion of a viral protein, or a viral protein with internal deletions,which has the ability to form VLPs under conditions that favor VLPformation. Accordingly, the polypeptide may comprise the full-lengthsequence, fusions, fragments, truncated and partial sequences, as wellas analogs and precursor forms of the reference molecule. Examples aredisclosed herein, but can include VP2 proteins alone, or in combinationwith VP3 proteins, thereby forming VLPs. Thus, a “particle-formingpolypeptide” derived from VP2 of IBDV includes, but is not limited to,full-length or near full-length viral protein, a fragment thereof, afusion, or a viral protein with internal deletions, which has theability to form VLPs under conditions that favor VLP formation.“Particle-forming polypeptide” also includes, but is not limited to,deletions, additions and substitutions to the sequence, so long as thepolypeptide retains the ability to form a VLP. “Particle-formingpolypeptide” also includes, but is not limited to, natural variations ofthe specified polypeptide since variations in coat proteins often occurbetween viral isolates as well as deletions, additions and substitutionsthat do not naturally occur in the reference protein, so long as theprotein retains the ability to form a VLP.

Preferred substitutions are those which are conservative in nature,i.e., those substitutions that take place within a family of amino acidsthat are related in their side chains. Specifically, amino acids aregenerally divided into four families: (1) acidic—aspartate andglutamate; (2) basic—lysine, arginine, histidine; (3) non-polar—alanine,valine, leucine, isoleucine, proline, phenylalanine, methionine,tryptophan; and (4) uncharged polar—glycine, asparagine, glutamine,cysteine, serine threonine, tyrosine. Phenylalanine, tryptophan, andtyrosine are sometimes classified as aromatic amino acids.

“Peptide” as used herein refers to any peptide, oligopeptide,polypeptide, gene product, expression product, or protein. For example,a peptide can be a receptor. A polypeptide is comprised of consecutiveamino acids. The term “polypeptide” encompasses naturally occurring orsynthetic molecules.

In addition, as used herein, the term “peptide” or “polypeptide” refersto amino acids joined to each other by peptide bonds or modified peptidebonds, e.g., peptide isosteres, etc. and may contain modified aminoacids other than the 20 gene-encoded amino acids. Polypeptides can bemodified by either natural processes, such as post-translationalprocessing, or by chemical modification techniques which are well knownin the art. Modifications can occur anywhere in the polypeptide,including the peptide backbone, the amino acid side-chains and the aminoor carboxyl termini. The same type of modification can be present in thesame or varying degrees at several sites in a given polypeptide. Also, agiven polypeptide can have many types of modifications. Modificationsinclude, without limitation, acetylation, acylation, ADP-ribosylation,amidation, covalent cross-linking or cyclization, covalent attachment offlavin, covalent attachment of a heme moiety, covalent attachment of anucleotide or nucleotide derivative, covalent attachment of a lipid orlipid derivative, covalent attachment of a phosphytidylinositol,disulfide bond formation, demethylation, formation of cysteine orpyroglutamate, formylation, gamma-carboxylation, glycosylation, GPIanchor formation, hydroxylation, iodination, methylation,myristolyation, oxidation, pergylation, proteolytic processing,phosphorylation, prenylation, racemization, selenoylation, sulfation,and transfer-RNA mediated addition of amino acids to protein such asarginylation. (See Proteins—Structure and Molecular Properties 2nd Ed.,T. E. Creighton, W.H. Freeman and Company, New York (1993);Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed.,Academic Press, New York, pp. 1-12 (1983)).

As used herein, the term “amino acid sequence” refers to a list ofabbreviations, letters, characters or words representing amino acidresidues.

Pharmaceutical Compositions

Polyvalent compositions produced as described herein can be used toelicit an immune response when administered to a subject. As discussedabove, the compositions can comprise a variety of antigens (e.g., one ormore modified IBVD antigens from one or more strains or isolates).Purified polyvalent compositions can be administered to a vertebratesubject, usually in the form of vaccine compositions. Combinationvaccines may also be used, where such vaccines contain, for example,other subunit proteins derived from IBDV or other organisms and/or genedelivery vaccines encoding such antigens.

In one aspect, disclosed herein are vaccines comprising the VP2s and/orVLPs disclosed herein. It is understood that the disclosed vaccines canbe therapeutic or prophylactic. Thus, for example, disclosed herein arevaccines comprising VP2s or VLps comprising a polyvalent or monovalentVP2 trimer in the VLP. For example, disclosed herein are vaccineswherein the VLP can comprise one or more VP2 monomers of IBDV variantstrain USA08MD34p, and/or one or more VP2 monomer of IBDV classic strainMo195. In another example, the vaccine can comprise VP2s or VLPscomprising polyvalent or monovalent VP2 trimers wherein the trimercomprises at least one VP2 monomer of IBDV selected from the groupconsisting of variant strain USA08MD34p, a VP2 monomer of IBDV classicstrain Mo195 and a VP2 monomer from an IBDV strain which is not IBDVvariant strain USA08MD34p and is not IBDV classic strain Mo195. Inanother example, the vaccine can comprise VP2s or VLPs comprisingpolyvalent or monovalent VP2 trimers wherein the trimer comprises atleast one or more VP2 monomer of IBDV selected from the group consistingof USA08MD34p, Mo195, UPM97/61 (AF247006), UPM94/273 (AF527039), OKYM(D49706), UK661 (X92760), IBDKS (L42284), D6948 (AF240686), BD3/99(AF362776), Tasik94 (AF322444), Chinju (AF508176), HK46 (AF092943), SH95(AF13474), Gx (AY 444873), SDH1 (AY323952) and T09 (AY099456), D78(AF499929), Cu-1M (AF362771), P2 (X84034), CT (AJ310185), CEF94(AF194428), PBG-98 (D00868), JD1 (AF321055), HZ-2 (AF321054), TADGumboro, Delvax, Gumboro LZD, IBDVAC, 89163, Farager 52/70, and Edgar(AF462026).

Therefore, disclosed herein are compositions comprising the polyvalentVP2s and/or VLPs described herein, along with a pharmaceuticallyacceptable carrier. VLPs and VP2s produced as described herein can beused to elicit an immune response when administered to a subject.Purified VLPs or VP2s can be administered to a subject, usually in theform of vaccine compositions. VP2/VLP immune-stimulating (or vaccine)compositions can include various excipients, adjuvants, carriers,auxiliary substances, modulating agents, and the like. The immunestimulating compositions can include an amount of the VP2/antigen orVLP/antigen sufficient to mount an immunological response. Anappropriate effective amount can be determined by one of skill in theart.

By an “effective amount” of a compound as provided herein is meant asufficient amount of the compound to provide the desired effect. Forexample, an effective amount of a compound can refer to a sufficientamount of the compound to generate an immune response. The exact amountrequired will vary from subject to subject, depending on the species,age, and general condition of the subject, the severity of disease (orunderlying genetic defect) that is being treated, the particularcompound used, its mode of administration, and the like. Thus, it is notpossible to specify an exact “effective amount.” However, an appropriate“effective amount” may be determined by one of ordinary skill in the artusing only routine experimentation.

Typically, an effective amount will fall in a relatively broad rangethat can be determined through routine trials and will generally be anamount on the order of about 0.1 μg to about 10 (or more) mg, morepreferably about 1 μg to about 300 μg, even more preferably 25 μg to 50μg of VP2/antigen or VLP/antigen. Sub-viral structure vaccines arepurified from the cell culture medium and formulated with theappropriate buffers and additives, such as a) preservatives orantibiotics; b) stabilizers, including proteins or organic compounds; c)adjuvants or immuno-modulators for enhancing potency and modulatingimmune responses (humoral and cellular) to the vaccine; or d) moleculesthat enhance presentation of vaccine antigens to specifics cell of theimmune system. This vaccine can be prepared in a freeze-dried(lyophilized) form in order to provide for appropriate storage andmaximize the shelf-life of the preparation. This will allow for stockpiling of vaccine for prolonged periods of time maintainingimmunogenicity, potency and efficacy.

Pharmaceutical Carriers/Delivery of Pharmaceutical Products

As described above, the compositions can also be administered in vivo ina pharmaceutically acceptable carrier. By “pharmaceutically acceptable”is meant a material that is not biologically or otherwise undesirable,i.e., the material may be administered to a subject, along with thenucleic acid or vector, without causing any undesirable biologicaleffects or interacting in a deleterious manner with any of the othercomponents of the pharmaceutical composition in which it is contained.The carrier would naturally be selected to minimize any degradation ofthe active ingredient and to minimize any adverse side effects in thesubject, as would be well known to one of skill in the art.

The compositions may be administered orally, parenterally (e.g.,intravenously), by intramuscular injection, by intraperitonealinjection, transdermally, extracorporeally, topically or the like,including topical intranasal administration or administration byinhalant. As used herein, “topical intranasal administration” meansdelivery of the compositions into the nose and nasal passages throughone or both of the nares and can comprise delivery by a sprayingmechanism or droplet mechanism, or through aerosolization of the nucleicacid or vector. Administration of the compositions by inhalant can bethrough the nose or mouth via delivery by a spraying or dropletmechanism. Delivery can also be directly to any area of the respiratorysystem (e.g., lungs) via intubation. The exact amount of thecompositions required will vary from subject to subject, depending onthe species, age, weight and general condition of the subject, theseverity of the allergic disorder being treated, the particular nucleicacid or vector used, its mode of administration and the like. Thus, itis not possible to specify an exact amount for every composition.However, an appropriate amount can be determined by one of ordinaryskill in the art using only routine experimentation given the teachingsherein.

Parenteral administration of the composition, if used, is generallycharacterized by injection. Injectables can be prepared in conventionalforms, either as liquid solutions or suspensions, solid forms suitablefor solution of suspension in liquid prior to injection, or asemulsions. A more recently revised approach for parenteraladministration involves use of a slow release or sustained releasesystem such that a constant dosage is maintained. See, e.g., U.S. Pat.No. 3,610,795, which is incorporated by reference herein.

The materials may be in solution, suspension (for example, incorporatedinto microparticles, liposomes, or cells). These may be targeted to aparticular cell type via antibodies, receptors, or receptor ligands. Thefollowing references are examples of the use of this technology totarget specific proteins to tumor tissue (Senter, et al., BioconjugateChem., 2:447-451, (1991); Bagshawe, K. D., Br. J. Cancer, 60:275-281,(1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, etal., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., CancerImmunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie,Immunolog. Reviews, 129:57-80, (1992); and Roffler, et al., Biochem.Pharmacol, 42:2062-2065, (1991)). Vehicles such as “stealth” and otherantibody conjugated liposomes (including lipid mediated drug targetingto colonic carcinoma), receptor mediated targeting of DNA through cellspecific ligands, lymphocyte directed tumor targeting, and highlyspecific therapeutic retroviral targeting of murine glioma cells invivo. The following references are examples of the use of thistechnology to target specific proteins to tumor tissue (Hughes et al.,Cancer Research, 49:6214-6220, (1989); and Litzinger and Huang,Biochimica et Biophysica Acta, 1104:179-187, (1992)). In general,receptors are involved in pathways of endocytosis, either constitutiveor ligand induced. These receptors cluster in clathrin-coated pits,enter the cell via clathrin-coated vesicles, pass through an acidifiedendosome in which the receptors are sorted, and then either recycle tothe cell surface, become stored intracellularly, or are degraded inlysosomes. The internalization pathways serve a variety of functions,such as nutrient uptake, removal of activated proteins, clearance ofmacromolecules, opportunistic entry of viruses and toxins, dissociationand degradation of ligand, and receptor-level regulation. Many receptorsfollow more than one intracellular pathway, depending on the cell type,receptor concentration, type of ligand, ligand valency, and ligandconcentration. Molecular and cellular mechanisms of receptor-mediatedendocytosis has been reviewed (Brown and Greene, DNA and Cell Biology10:6, 399-409 (1991)).

Pharmaceutically Acceptable Carriers

The compositions, including antibodies, can be used therapeutically incombination with a pharmaceutically acceptable carrier.

Suitable carriers and their formulations are described in Remington: TheScience and Practice of Pharmacy (19th ed.) ed. A. R. Gennaro, MackPublishing Company, Easton, Pa. 1995. Typically, an appropriate amountof a pharmaceutically-acceptable salt is used in the formulation torender the formulation isotonic. Examples of thepharmaceutically-acceptable carrier include, but are not limited to,saline, Ringer's solution and dextrose solution. The pH of the solutionis preferably from about 5 to about 8, and more preferably from about 7to about 7.5. Further carriers include sustained release preparationssuch as semipermeable matrices of solid hydrophobic polymers containingthe antibody, which matrices are in the form of shaped articles, e.g.,films, liposomes or microparticles. It will be apparent to those personsskilled in the art that certain carriers may be more preferabledepending upon, for instance, the route of administration andconcentration of composition being administered.

Pharmaceutical carriers are known to those skilled in the art. Thesemost typically would be standard carriers for administration of drugs tohumans, including solutions such as sterile water, saline, and bufferedsolutions at physiological pH. The compositions can be administeredintramuscularly or subcutaneously. Other compounds will be administeredaccording to standard procedures used by those skilled in the art.

Pharmaceutical compositions may include carriers, thickeners, diluents,buffers, preservatives, surface active agents and the like in additionto the molecule of choice. Pharmaceutical compositions may also includeone or more active ingredients such as antimicrobial agents,antiinflammatory agents, anesthetics, and the like.

The pharmaceutical composition may be administered in a number of waysdepending on whether local or systemic treatment is desired, and on thearea to be treated. Administration may be topically (includingophthalmically, vaginally, rectally, intranasally), orally, byinhalation, or parenterally, for example by intravenous drip,subcutaneous, intraperitoneal or intramuscular injection. The disclosedantibodies can be administered intravenously, intraperitoneally,intramuscularly, subcutaneously, intracavity, or transdermally.

Preparations for parenteral administration include sterile aqueous ornon-aqueous solutions, suspensions, and emulsions. Examples ofnon-aqueous solvents are propylene glycol, polyethylene glycol,vegetable oils such as olive oil, and injectable organic esters such asethyl oleate. Aqueous carriers include water, alcoholic/aqueoussolutions, emulsions or suspensions, including saline and bufferedmedia. Parenteral vehicles include sodium chloride solution, Ringer'sdextrose, dextrose and sodium chloride, lactated Ringer's, or fixedoils. Intravenous vehicles include fluid and nutrient replenishers,electrolyte replenishers (such as those based on Ringer's dextrose), andthe like. Preservatives and other additives may also be present such as,for example, antimicrobials, anti-oxidants, chelating agents, and inertgases and the like.

Formulations for topical administration may include ointments, lotions,creams, gels, drops, suppositories, sprays, liquids and powders.Conventional pharmaceutical carriers, aqueous, powder or oily bases,thickeners and the like may be necessary or desirable.

Compositions for oral administration include powders or granules,suspensions or solutions in water or non-aqueous media, capsules,sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers,dispersing aids or binders may be desirable.

Some of the compositions may potentially be administered as apharmaceutically acceptable acid- or base-addition salt, formed byreaction with inorganic acids such as hydrochloric acid, hydrobromicacid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, andphosphoric acid, and organic acids such as formic acid, acetic acid,propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid,malonic acid, succinic acid, maleic acid, and fumaric acid, or byreaction with an inorganic base such as sodium hydroxide, ammoniumhydroxide, potassium hydroxide, and organic bases such as mono-, di-,trialkyl and aryl amines and substituted ethanolamines.

Additionally, these carriers can function as immunostimulating agents(“adjuvants”). Exemplary adjuvants include, but are not limited to: (1)aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate,aluminum sulfate, etc.; (2) oil-in-water emulsion formulations (with orwithout other specific immunostimulating agents such as muramyl peptides(see below) or bacterial cell wall components), such as for example (a)MF59 (International Publication No. WO 90/14837), containing 5%Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing variousamounts of MTP-PE (see below), although not required) formulated intosubmicron particles using a microfluidizer such as Model 110Ymicrofluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10%Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP(see below) either microfluidized into a submicron emulsion or vortexedto generate a larger particle size emulsion, and (c) Ribi™ adjuvantsystem (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene,0.2% Tween 80, and one or more bacterial cell wall components from thegroup consisting of monophosphorylipid A (MPL), trehalose dimycolate(TDM), and cell wall skeleton (CWS), preferably MPL+CWS (Detoxu); (3)saponin adjuvants, such as Stimulom™. (Cambridge Bioscience, Worcester,Mass.) may be used or particle generated therefrom such as ISCOMs(immunostimulating complexes); (4) Complete Freunds Adjuvant (CFA) andIncomplete Freunds Adjuvant (IFA); (5) cytokines, such as interleukins(IL-1, IL-2, etc.), macrophage colony stimulating factor (M-CSF), tumornecrosis factor (TNF), beta chemokines (MIP, 1-alpha, 1-beta Rantes,etc.); (6) detoxified mutants of a bacterial ADP-ribosylating toxin suchas a cholera toxin (CT), a pertussis toxin (PT), or an E. coliheat-labile toxin (LT), particularly LT-K63 (where lysine is substitutedfor the wild-type amino acid at position 63) LT-R72 (where arginine issubstituted for the wild-type amino acid at position 72), CT-S109 (whereserine is substituted for the wild-type amino acid at position 109), andPT-K9/G129 (where lysine is substituted for the wild-type amino acid atposition 9 and glycine substituted at position 129) (see, e.g.,International Publication Nos. WO93/13202 and WO92/19265); and (7) othersubstances that act as immunostimulating agents to enhance theeffectiveness of the composition. Muramyl peptides include, but are notlimited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),N-acteyl-normuramyl-L-alanyl-D-isogluatme (nor-MDP),N-acetylmuramyl-L-alanyl-D-isogluatminyl-L-alanine-2-(1′-2′-dipalmitoyl-s-n-glycero-3-huydroxyphosphoryloxy)-ethylamine(MTP-PE), etc.

Examples of suitable immunomodulatory molecules for use herein includeadjuvants described above and the following: IL-1 and IL-2 (Karupiah etal. (1990) J. Immunology 144:290-298, Weber et al. (1987) J. Exp. Med.166:1716-1733, Gansbacher et al. (1990) J. Exp. Med. 172:1217-1224, andU.S. Pat. No. 4,738,927-); IL-3 and IL-4 (Tepper et al. (1989) Cell57:503-512, Golumbek et al. (1991) Science 254:713-716, and U.S. Pat.No. 5,017,691); IL-5 and IL-6 (Brakenhof et al. (1987) J. Immunol.139:4116-4121, and International Publication No. WO 90/06370); IL-7(U.S. Pat. No. 4,965,195); IL-8, IL-9, IL-10, IL-11, IL-12, and IL-13(Cytokine Bulletin, Summer 1994); IL-14 and IL-15; alpha interferon(Finter et al. (1991) Drugs 42:749-765, U.S. Pat. Nos. 4,892,743 and4,966,843, International Publication No. WO 85/02862, Nagata et al.(1980) Nature 284:316-320, Familletti et al. (1981) Methods in Enz.78:387-394, Twu et al. (1989) Proc. Natl. Acad. Sci. USA 86:2046-2050,and Faktor et al. (1990) Oncogene 5:867-872); .beta.-interferon (Seif etal. (1991) J. Virol. 65:664-671); γ-interferons (Watanabe et al. (1989)Proc. Natl. Acad. Sci. USA 86:9456-9460, Gansbacher et al. (1990) CancerResearch 50:7820-7825, Maio et al. (1989) Can. Immunol. Immunother.30:34-42, and U.S. Pat. Nos. 4,762,791 and 4,727,138); G-CSF (U.S. Pat.Nos. 4,999,291 and 4,810,643); GM-CSF (International Publication No. WO85/04188); tumor necrosis factors (TNFs) (Jayaraman et al. (1990) J.Immunology 144:942-951); CD3 (Krissanen et al. (1987) Immunogenetics26:258-266); ICAM-1 (Altman et al. (1989) Nature 338:512-514, Simmons etal. (1988) Nature 331:624-627); ICAM-2, LFA-1, LFA-3 (Wallner et al.(1987) J. Exp. Med. 166:923-932); MHC class I molecules, MHC class IImolecules, B7.1-.beta.2-microglobulin (Pames et al. (1981) Proc. Natl.Acad. Sci. USA 78:2253-2257); chaperones such as calnexin; andMHC-linked transporter proteins or analogs thereof (Powis et al. (1991)Nature 354:528-531). Immunomodulatory factors can also be agonists,antagonists, or ligands for these molecules. For example, soluble formsof receptors can often behave as antagonists for these types of factors,as can mutated forms of the factors themselves.

Administration

The VP2s, VLPs and compositions comprising them can be administered to asubject by any mode of delivery, including, for example, by parenteralinjection (e.g. subcutaneously, intraperitoneally, intravenously,intramuscularly, or to the interstitial space of a tissue), or byrectal, oral (e.g. tablet, spray), vaginal, topical, transdermal (e.g.see WO99/27961) or transcutaneous (e.g. see WO02/074244 andWO02/064162), intranasal (e.g. see WO03/028760), ocular, aural,pulmonary or other mucosal administration. In one example, thecomposition is administered in a mist. Multiple doses can beadministered by the same or different routes.

The VLPs (and VLP-containing compositions) can be administered prior to,concurrent with, or subsequent to delivery of other vaccines. Also, thesite of VLP administration may be the same or different as other vaccinecompositions that are being administered.

Dosage treatment with the VLP composition can be a single dose scheduleor a multiple dose schedule. A multiple dose schedule is one in which aprimary course of vaccination may be with 1-10 separate doses, followedby other doses given at subsequent time intervals, chosen to maintainand/or reinforce the immune response. The dosage regimen will also, atleast in part, be determined by the potency of the modality, the vaccinedelivery employed, the need of the subject and be dependent on thejudgment of the practitioner. In one example, two doses are given, andare administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more daysapart. In one embodiment, the first two doses are given 7-10 days apart.In another embodiment the doses can be 3-4 weeks apart.

The vaccines disclosed herein can provide antibody titers of 100, 200,300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500,4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500,10000, 10500, 11000, 11500, and 12000, and titers of 100, 200, 300, 400,500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500,5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000,10500, 11000, 11500, and 12000, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20weeks post-immunization following 1, 2, 3, 4, 5, or more immunizations.

The dose of VLP or VP2 administered can vary, depending on the age orcondition of the subject. Typically, for a VLP, the dose is between15-75 μg, and more specifically between 25-50 μg.

Kits

Disclosed herein are kits comprising the one or more of thecompositions, including, but not limited to, the polyvalent VP2s, VLPs,nucleic acids, antibodies, or cells disclosed herein.

Aquabirnavirus

Infectious pancreatic necrosis virus is the causative agent ofinfectious pancreatic necrosis disease (IPN) that infects salmonids andremains a serious problem in the aquaculture industry. IPN is especiallycontagious and destructive to juvenile trout and salmon. Highly virulentstrains may cause greater than 70% mortality in hatchery stocks over aperiod of two months. This disease is especially destructive in salmonideggs and fingerlings. Survivors of infection can remain lifelongasymptomatic carriers and serve as reservoirs of infection, sheddingvirus in their feces and reproductive products. Losses due to IPNV onsalmon smoltification have been estimated at 5%. Economic losses due toIPNV in aquaculture were estimated to be over 560 million in 1996. Thishas been reduced as vaccines for salmonids became available based onkilled virus or recombinantly produced viral peptides. However, thesevaccines are not completely effective and can only be used in fairlylarge fish due to the reliance on injection for vaccination.

Polyvalent VP2s and mosaic VLPs, and compositions of the invention canalso be from members of the aquabirnavirus genus of birnavirus family.In particular, the species infectious pancreatic necrosis virus (IPNV)can be used to form polyvalent VP2s and mosaic VLPs as described hereinand exemplified for IBDV.

Production of VP2s and VLPs for IPNV can be accomplished using thetechniques described herein for IBDV utilizing sequences, for example,of pVP2 (ACY35990) and VP3 (AAM90322) from IPNV and otheraquabirnaviruses. In particular, the IPNV sequences can be substitutedfor the IBDV sequences set forth in the examples. The IPNV pVP2 gene canbe amplified using RT-PCR and specific primers for that gene. The IPNVVP3 gene can also be amplified using RT-PCR and specific primers for itssequence. The amplified genes can then be ligated into a Baculovirusexpression vector (pVL1392) and then used to transfect BaculovirusesRecombinant Baculoviruses containing either the pVP2 or VP3 genes fromIPNV can be used to express their respective proteins. Co-expression ofthe pVP2 and VP3 proteins in insect cells can be conducted to produceVLPs. The VLPs can be administered to fish for prevention of thediseases associated with IPNV in fish. Examples of such administrationcan be found, for example, in US 2010/0092521 A1, herein incorporated byreference in its entirety. The VLPs can also be used to detect thepresence of IPNV in a sample, as set forth for IBDV herein.

“Aquatic animal”, as used herein, includes any multi-cellular organismthat lives in water, typically fish. Preferably, said aquatic animal isan animal belonging to a fish species reared by aquaculture.Illustrative examples of said aquatic animals include teleost fish, suchas vertebrate fish, e.g. salmonids (e.g., rainbow trout, salmon, etc.),carp, turbot, gilthead sea bream, sea bass, etc.

Disclosed herein is a method of eliciting an immune response againstIPNV in a subject comprising administering to the subject an IPNVpolyvalent VP2, and/or mosaic VLP, composition, or nucleic acid encodingthe VP2/VLP. Another aspect of the invention also relates to a vaccinecomprising IPNV polyvalent VP2 and/mosaic VLPs. The vaccine can be usedto protect aquatic animals that can be infected by aquatic animalpathogens. In a particular embodiment, said pathogens are pathogens ofaquatic animals reared in aquaculture installations. The vaccine of theinvention can be administered by any appropriate route of administrationthat results in an immune response to protect against the pathogen inquestion, for which the vaccine will be formulated in a manner that issuitable for the chosen route of administration. Although the vaccine ofthe invention can be administered orally, intramuscularly, by particlebombardment or by spraying using conventional methods (U.S. Pat. No.5,780,448) for the simultaneous immunisation of a large number ofaquatic animals, another method is to submerge said aquatic animals in asolution comprising the vaccine of the invention. To do this, thevaccine of the invention can be prepared in the form of an aqueoussolution or suspension, in a pharmaceutically acceptable vehicle, suchas saline solution, phosphate buffered saline (PBS), or any otherpharmaceutically acceptable vehicle.

The vaccine of the invention can be prepared using conventional methodsknown by a person skilled in the art. In a particular embodiment, saidvaccine can be prepared using the mixture, if applicable, of a vector ofthe invention, optionally having one or more adjuvants and/orpharmaceutically acceptable vehicles.

Furthermore, another aspect of the invention relates to a method forsimultaneously administering a vaccine to a plurality of aquatic animals(mass vaccination) that comprises the immersion of a plurality ofaquatic animals in a bath containing the vaccine and the sonication ofthe bath containing said aquatic animals and said vaccine. Other methodsof IPNV vaccine administration can be found, for example, in US2007/0248623 A1, herein incorporated by reference in its entirety forits teaching concerning IPNV.

Disclosed herein is a polyvalent VP2 trimer of infectious pancreaticnecrosis virus (IPNV), wherein the polyvalent VP2 trimer comprises threeVP2 monomers, and wherein at least one of the VP2 monomers is from adifferent strain of IPNV than the other monomers.

In some embodiments, the VP2 monomers are each independently from anIPNV strain selected from the group consisting of IPNV2, IPNV10, Te(AF342731; England), C1 (AF342732; Canada), Ab (AF342729; Denmark), He(AF342730; Germany), C2 (AF342733; Canada), C3 (AF342734; Canada), SP(AF342728; Denmark), YTAV (AY283781; Japan), WB (AF342727; USA), andJasper (AF342735; Canada).

In some embodiments, the at least one of the VP2 monomers is from IPNV2and at least one of the VP2 monomers is from IPNV10. In someembodiments, the at least one of the VP2 monomers is SEQ ID NO:26 and atleast one of the VP2 monomers is SEQ ID NO:28.

In some embodiments, disclosed herein is a virus like particle (VLP)comprising VP3 proteins from at least one strain of infectiouspancreatic necrosis virus (IPNV) and a polyvalent VP2 trimer ofinfectious pancreatic necrosis virus (IPNV), wherein the polyvalent VP2trimer comprises three VP2 monomers, and wherein at least one of the VP2monomers is from a different strain of IPNV than the other monomers.

In some embodiments, the at least one of the VP2 monomers is from anIPNV strain selected from the group consisting of IPNV2, IPNV10, Te(AF342731; England), C1 (AF342732; Canada), Ab (AF342729; Denmark), He(AF342730; Germany), C2 (AF342733; Canada), C3 (AF342734; Canada), SP(AF342728; Denmark), YTAV (AY283781; Japan), WB (AF342727; USA), andJasper (AF342735; Canada).

In some embodiments, the at least one of the VP2 monomers is from IPNV2.In some embodiments, the at least one of the VP2 monomers is SEQ IDNO:26. In some embodiments, the at least one of the VP2 monomers is fromIPNV10. In some embodiments, the at least one of the VP2 monomers is SEQID NO:28. In some embodiments, the at least one of the VP2 monomers isfrom IPNV2 and at least one of the VP2 monomers is from IPNV10. In someembodiments, the at least one of the VP2 monomers is SEQ ID NO:26 and atleast one of the VP2 monomers is SEQ ID NO:28.

In some embodiments, two VP2 monomers from IPNV2 (SEQ ID NO:26) and oneVP2 monomer from IPNV10 (SEQ ID NO:28). In some embodiments, one VP2monomer from IPNV2 (SEQ ID NO:26) and two VP2 monomers from IPNV10 (SEQID NO:28).

The IPNV2 and IPNV10 virus sequences are both in Genogroup 1, but theirsequences are not identical. Genogroup 1 contains both serotype A1 andA9 strains. The IPNV2 and IPNV10 sequences are most similar to the WBand Jasper strains.

In some embodiments, the VP3 proteins are from IPNV10. In someembodiments, the VP3 proteins are SEQ ID NO:30. In some embodiments, theVP3 proteins are from IPNV2. In some embodiments, the VP3 proteins arefrom more than one IPNV strain.

In some embodiments, the VP3 proteins are from an IPNV strain selectedfrom the group consisting of IPNV2, IPNV10, Te (AF342731; England), C1(AF342732; Canada), Ab (AF342729; Denmark), He (AF342730; Germany), C2(AF342733; Canada), C3 (AF342734; Canada), SP (AF342728; Denmark), YTAV(AY283781; Japan), WB (AF342727; USA), and Jasper (AF342735; Canada).

Disclosed herein is a composition comprising a virus like particle (VLP)comprising VP3 proteins from at least one strain of infectiouspancreatic necrosis virus (IPNV) and a polyvalent VP2 trimer ofinfectious pancreatic necrosis virus (IPNV), wherein the polyvalent VP2trimer comprises three VP2 monomers, and wherein at least one of the VP2monomers is from a different strain of IPNV than the other monomers, anda pharmaceutically acceptable carrier.

Disclosed herein is an isolated host cell expressing a virus likeparticle (VLP) comprising VP3 proteins from at least one strain ofinfectious pancreatic necrosis virus (IPNV) and a polyvalent VP2 trimerof infectious pancreatic necrosis virus (IPNV), wherein the polyvalentVP2 trimer comprises three VP2 monomers, and wherein at least one of theVP2 monomers is from a different strain of IPNV than the other monomers.

In some embodiments, the cell is an insect cell. In some embodiments,the insect cell is a Sf9 cell.

Disclosed herein is a method of eliciting an immune response againstIPNV in a subject comprising administering to the subject a compositioncomprising a virus like particle (VLP) comprising VP3 proteins from atleast one strain of infectious pancreatic necrosis virus (IPNV) and apolyvalent VP2 trimer of infectious pancreatic necrosis virus (IPNV),wherein the polyvalent VP2 trimer comprises three VP2 monomers, andwherein at least one of the VP2 monomers is from a different strain ofIPNV than the other monomers.

In some embodiments, the subject is a fish. In some embodiments, thefish is a salmonid. In some embodiments, the fish is a salmon, trout(for example, rainbow trout), char, or other freshwater whitefish. Insome embodiments, the fish is a carp, turbot, gilthead sea bream, seabass, etc.

In some embodiments, the method further comprising administering to thesubject a virulent IPNV to monitor the immune response.

In some embodiments, the composition is administered in a single dose.In some embodiments, the composition is administered in two doses.

Methods

Immune Response

Disclosed herein are methods of eliciting an immune response againstIBDV in a subject comprising administering to the animal one or moreVP2s or VLPs, or a composition or nucleic acid thereof. The immuneresponse can be considered to be efficacious if the desired result isobtained.

By “efficacy,” “efficacious,” or “sufficiency” means the ability tofunction as intended. For example, an “efficacious” immune response is aresponse that is able to afford the subject an acceptable degree ofimmune protection from the immunizing antigen. Thus, the present methodsdisclose methods of assessing the ability of an immune response toprovide immune protection against future antigenic encounter.Traditionally, such methods involve antigenic challenge. It isunderstood that the present methods provide an alternative means toachieve the goal of antigenic challenge and can be used separately or inconjunction with a challenge to determine efficacy or sufficiency.

The term “sufficient or effective immune response” is used to describean immune response of a large enough magnitude to provide an acceptableimmune protection to the subject against future antigen encounter. It isunderstood that immune protection does not necessarily mean preventionof future antigenic encounter (e.g., infection), nor is it limited to alack of any pathogenic symptoms. “Immune protection” means a preventionof the full onset of a pathogenic condition. Thus, in one embodiment, a“sufficient immune response” is a response that reduces the symptoms,magnitude, or duration of an infection or other disease condition whencompared with an appropriate control. The control can be a subject thatis exposed to an antigen before or without a sufficient immune response.

For example, “protective against” can mean that the subject is preventedfrom acquiring one or more symptoms associated with IBD virus infection,or from having any negative response when exposed to the virus, or isprevented from dying from the disease, or dying from the disease withina given time period, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, or 16 weeks, or 5, 6, 7, 8, 9, 10, 11, or 12 months, or anyamount of time in between.

For example, the survival rate of a group of subjects to which themolecules are administered can have a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65,66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83,84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%improvement in mortality rate. By “mortality rate” is meant that thesubject has an increased lifespan. For example, if 100 broilers aregiven a vaccine (as disclosed herein) which immunizes them against IBDV,and 95% of them survive past a given time, such as 3-4 weeks, then thevaccine is considered to impart a 95% survival rate.

In another example, the subject (such as a parental line, broiler orlayer) can be administered a virulent IBDV to monitor the immuneresponse. As outlined above, this can increase the lifespan of thesubject by a given time period. The virulent IBDV can also beadministered to a subject that has not received the vaccine (a control),and both can be monitored to determine the effectiveness of the vaccine.The immune response for both can be measured either by observation ofthe onset of symptoms of IBDV, or by monitoring the immune response ofthe subjects.

As outlined herein, there are multiple strains of IBDV, and any of thesestrains can be given to a subject who has been vaccinated, and/or acontrol, in order to monitor the effectiveness of the vaccine. Examplesof such strains include, but are not limited to, the V1 variant virusand STC classic virus strain.

Disclosed herein are methods of reducing immunosuppression in a subjectcomprising the steps of: providing a composition as disclosed herein,such as one comprising a VP2s or VLPs, and administering saidcomposition to the subject. As outlined herein, the subject can be anavian, such as a chicken. By “reducing immunosuppression” is meant thatthe amount of immunosuppression in a given subject after vaccination isless than that in an unvaccinated subject. By “immunosuppression” ismeant suppression of the immune systems by IBDV. The amount thatimmunosuppression is reduced in a given individual subject can be 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58,59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76,77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,95, 96, 97, 98, 99, or 100% when compared to a control.

Also disclosed is a method of reducing death in a subject comprising thesteps of: providing a composition comprising a VP2s or VLPs, asdescribed herein, and administering said composition to the subject. Asdiscussed herein, by “reducing death” is meant increasing survival rateof the subject as compared to a control.

As used herein, the term “treatment” refers to the medical management ofa subject with the intent to produce a therapy, cure, ameliorate,stabilize, or prevent a disease, pathological condition, or disorder.This term includes active treatment, that is, treatment directedspecifically toward the improvement of a disease, pathologicalcondition, or disorder, and also includes causal treatment, that is,treatment directed toward removal of the cause of the associateddisease, pathological condition, or disorder. In addition, this termincludes palliative treatment, that is, treatment designed for therelief of symptoms rather than the curing of the disease, pathologicalcondition, or disorder; preventative treatment, that is, treatmentdirected to minimizing or partially or completely inhibiting thedevelopment of the associated disease, pathological condition, ordisorder; and supportive treatment, that is, treatment employed tosupplement another specific therapy directed toward the improvement ofthe associated disease, pathological condition, or disorder.

The treatment can be any reduction from native levels and can be but isnot limited to the complete ablation of the disease, condition, or thesymptoms of the disease or condition. Thus, the reduction can be a 10,20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction inbetween as compared to native or control levels.

By “treat” is meant to administer a compound or molecule to a subject,such as an animal (for example, a chicken), that has a condition ordisease, such as IBDV, an increased susceptibility for developing such adisease, in order to prevent or delay a worsening of the effects of thedisease or condition, or to partially or fully reverse the effects ofthe disease. To “treat” can also refer to non-pharmacological methods ofpreventing or delaying a worsening of the effects of the disease orcondition, or to partially or fully reversing the effects of thedisease. For example, “treat” is meant to mean a course of action toprevent or delay a worsening of the effects of the disease or condition,or to partially or fully reverse the effects of the disease other thanby administering a compound.

By “prevent” is meant to minimize the chance that a subject who has asusceptibility for developing disease, such as IBDV induced disease,will develop a such a disease, or one or more symptoms associated withthe disease.

By “subject” is meant any member of the subphylum chordata, and inparticular the ayes class, although the methods and compositionsdisclosed herein are relevant to any animal that can for examplecontract IBDV (infectious bursal disease virus) or IPNV (infectiouspancreatic necrosis virus). Examples of members of the ayes classinclude, but are not limited to, those found in the superorderpalaeognathae:struthioniformes (ostriches, emus, kiwis, and allies), andtinamiformes (tinamous). Also included is the superorder neognathae,which includes anseriformes (waterfowl), galliformes (fowl, includingchickens, ducks, geese, guinea, quail, grouse, pheasant and turkeys),charadriiformes (gulls, button-quails, plovers and allies), gaviiformes(loons), podicipediformes (grebes), procellariiformes (albatrosses,petrels, and allies), sphenisciformes (penguins), pelecaniformes(pelicans and allies), phaethontiformes (tropicbirds), ciconiiformes(storks and allies), cathartiformes (New World vultures),phoenicopteriformes (flamingos), falconiformes (falcons, eagles, hawksand allies), gruiformes (cranes and allies), pteroclidiformes(sandgrouse), columbiformes (doves and pigeons), psittaciformes (parrotsand allies), cuculiformes (cuckoos and turacos), opisthocomiformes(hoatzin), strigiformes (owls), caprimulgiformes (nightjars and allies),apodiformes (swifts and hummingbirds), coraciiformes (kingfishers andallies), piciformes (woodpeckers and allies), trogoniformes (trogons),coliiformes (mousebirds), and passeriformes (passerines). The term doesnot denote a particular age. Thus, both adult and newborn individualsare intended to be covered. The system described above is intended forany animal capable of contracting IBDV.

Diagnostics

The VLPs disclosed herein can be used as a diagnostic tool to detect,for example IBDV or IPNV antibodies in a sample.

As used herein, the term “diagnosed” means having been subjected to anexamination by a person of skill, for example, a physician, and found tohave a condition that can be diagnosed or treated by the compounds,compositions, or methods disclosed herein. For example, “diagnosed withIBDV” means having been subjected to an examination by a person ofskill, for example, a veterinarian, and found to have a condition thatcan be diagnosed or treated by one or more of the compositions describedherein.

Examples of diagnostic tools include but are not limited to: Westernblot, immunoblot, enzyme-linked immunosorbant assay (ELISA),radioimmunoassay (RIA), immunoprecipitation, surface plasmon resonance,chemiluminescence, fluorescent polarization, phosphorescence,immunohistochemical analysis, matrix-assisted laserdesorption/ionization time-of-flight (MALDI-TOF) mass spectrometry,microcytometry, microarray, microscopy, fluorescence activated cellsorting (FACS), and flow cytometry, as well as assays based on aproperty of the protein including but not limited to enzymatic activityor interaction with other protein partners.

As seen in Example 2, the VLP antigens can react with serum antibodiesto IBDV and produce a positive result in the ELISA. Chicken serumsamples from birds not exposed to IBDV were negative in the assay. Theresults indicate that VLP antigens can be used in the ELISA to detectantibodies to IBDV strains.

Thus, this invention provides a method of detecting or determining thepresence of IBDV or IBDV in a sample comprising contacting a VLP of thisinvention with an antibody containing sample from a patient anddetecting the presence and/or absence of binding between the VLP and theantibodies in the sample.

Measuring Responsiveness

The immune response can be measured in a subject to assess the viabilityor usefulness of the composition, or to determine if multiple doses needto be administered. Immunoassays that involve the detection of assubstance, such as a protein or an antibody to a specific protein,include label-free assays, protein separation methods (i.e.,electrophoresis), solid support capture assays, or in vivo detection.Label-free assays are generally diagnostic means of determining thepresence or absence of a specific protein, or an antibody to a specificprotein, in a sample. Protein separation methods are additionally usefulfor evaluating physical properties of the protein, such as size or netcharge. Capture assays are generally more useful for quantitativelyevaluating the concentration of a specific protein, or antibody to aspecific protein, in a sample. Finally, in vivo detection is useful forevaluating the spatial expression patterns of the substance, i.e., wherethe substance can be found in a subject, tissue or cell.

Provided that the concentrations are sufficient, the molecular complexes([Ab-Ag]n) generated by antibody-antigen interaction are visible to thenaked eye, but smaller amounts may also be detected and measured due totheir ability to scatter a beam of light. The formation of complexesindicates that both reactants are present, and in immunoprecipitationassays a constant concentration of a reagent antibody is used to measurespecific antigen ([Ab-Ag]n), and reagent antigens are used to detectspecific antibody ([Ab-Ag]n). If the reagent species is previouslycoated onto cells (as in hemagglutination assay) or very small particles(as in latex agglutination assay), “clumping” of the coated particles isvisible at much lower concentrations.

The use of immunoassays to detect a specific protein can involve theseparation of the proteins by electrophoresis. Electrophoresis is themigration of charged molecules in solution in response to an electricfield. Their rate of migration depends on the strength of the field; onthe net charge, size and shape of the molecules and also on the ionicstrength, viscosity and temperature of the medium in which the moleculesare moving. As an analytical tool, electrophoresis is simple, rapid andhighly sensitive. It is used analytically to study the properties of asingle charged species, and as a separation technique.

Generally the sample is run in a support matrix such as paper, celluloseacetate, starch gel, agarose or polyacrylamide gel. The matrix inhibitsconvective mixing caused by heating and provides a record of theelectrophoretic run: at the end of the run, the matrix can be stainedand used for scanning, autoradiography or storage. In addition, the mostcommonly used support matrices—agarose and polyacrylamide—provide ameans of separating molecules by size, in that they are porous gels. Aporous gel may act as a sieve by retarding, or in some cases completelyobstructing, the movement of large macromolecules while allowing smallermolecules to migrate freely. Because dilute agarose gels are generallymore rigid and easy to handle than polyacrylamide of the sameconcentration, agarose is used to separate larger macromolecules such asnucleic acids, large proteins and protein complexes. Polyacrylamide,which is easy to handle and to make at higher concentrations, is used toseparate most proteins and small oligonucleotides that require a smallgel pore size for retardation.

In two-dimensional electrophoresis, proteins are fractionated first onthe basis of one physical property, and, in a second step, on the basisof another. For example, isoelectric focusing can be used for the firstdimension, conveniently carried out in a tube gel, and SDSelectrophoresis in a slab gel can be used for the second dimension. Oneexample of a procedure is that of O'Farrell, P. H., High ResolutionTwo-dimensional Electrophoresis of Proteins, J. Biol. Chem.250:4007-4021 (1975), herein incorporated by reference in its entiretyfor its teaching regarding two-dimensional electrophoresis methods.Other examples include but are not limited to, those found in Anderson,L and Anderson, N G, High resolution two-dimensional electrophoresis ofhuman plasma proteins, Proc. Natl. Acad. Sci. 74:5421-5425 (1977),Ornstein, L., Disc electrophoresis, L. Ann. N.Y. Acad. Sci. 121:321349(1964), each of which is herein incorporated by reference in itsentirety for teachings regarding electrophoresis methods. Laemmli, U.K.,Cleavage of structural proteins during the assembly of the head ofbacteriophage T4, Nature 227:680 (1970), which is herein incorporated byreference in its entirety for teachings regarding electrophoresismethods, discloses a discontinuous system for resolving proteinsdenatured with SDS. The leading ion in the Laemmli buffer system ischloride, and the trailing ion is glycine. Accordingly, the resolvinggel and the stacking gel are made up in Tris-HCl buffers (of differentconcentration and pH), while the tank buffer is Tris-glycine. Allbuffers contain 0.1% SDS.

One example of an protein expression profile assay as contemplated inthe current methods is Western blot analysis. Western blotting orimmunoblotting allows the determination of the molecular mass of aprotein and the measurement of relative amounts of the protein presentin different samples. Detection methods include chemiluminescence andchromagenic detection. Standard methods for Western blot analysis can befound in, for example, D. M. Bollag et al., Protein Methods (2d edition1996) and E. Harlow & D. Lane, Antibodies, a Laboratory Manual (1988),U.S. Pat. No. 4,452,901, each of which is herein incorporated byreference in their entirety for teachings regarding Western blotmethods. Generally, proteins are separated by gel electrophoresis,usually SDS-PAGE. The proteins are transferred to a sheet of specialblotting paper, e.g., nitrocellulose, though other types of paper, ormembranes, can be used. The proteins retain the same pattern ofseparation they had on the gel. The blot is incubated with a genericprotein (such as milk proteins) to bind to any remaining sticky placeson the nitrocellulose. An antibody is then added to the solution whichis able to bind to its specific protein.

The attachment of specific antibodies to specific immobilized antigenscan be readily visualized by indirect enzyme immunoassay techniques,usually using a chromogenic substrate (e.g. alkaline phosphatase orhorseradish peroxidase) or chemiluminescent substrates. Otherpossibilities for probing include the use of fluorescent or radioisotopelabels (e.g., fluorescein, 125I). Probes for the detection of antibodybinding can be conjugated anti-immunoglobulins, conjugatedstaphylococcal Protein A (binds IgG), or probes to biotinylated primaryantibodies (e.g., conjugated avidin/streptavidin).

The power of the technique lies in the simultaneous detection of aspecific protein by means of its antigenicity, and its molecular mass.Proteins are first separated by mass in the SDS-PAGE, then specificallydetected in the immunoassay step. Thus, protein standards (ladders) canbe run simultaneously in order to approximate molecular mass of theprotein of interest in a heterogeneous sample.

The gel shift assay or electrophoretic mobility shift assay (EMSA) canbe used to detect the interactions between DNA binding proteins andtheir cognate DNA recognition sequences, in both a qualitative andquantitative manner. Exemplary techniques are described in Ornstein L.,Disc electrophoresis—I: Background and theory, Ann. NY Acad. Sci.121:321-349 (1964), and Matsudiara, P T and DR Burgess, S D S microslablinear gradient polyacrylamide gel electrophoresis, Anal. Biochem.87:386-396 (1987), each of which is herein incorporated by reference inits entirety for teachings regarding gel-shift assays.

In a general gel-shift assay, purified proteins or crude cell extractscan be incubated with a labeled (e.g., 32P-radiolabeled) DNA or RNAprobe, followed by separation of the complexes from the free probethrough a nondenaturing polyacrylamide gel. The complexes migrate moreslowly through the gel than unbound probe. Depending on the activity ofthe binding protein, a labeled probe can be either double-stranded orsingle-stranded. For the detection of DNA binding proteins such astranscription factors, either purified or partially purified proteins,or nuclear cell extracts can be used. For detection of RNA bindingproteins, either purified or partially purified proteins, or nuclear orcytoplasmic cell extracts can be used. The specificity of the DNA or RNAbinding protein for the putative binding site is established bycompetition experiments using DNA or RNA fragments or oligonucleotidescontaining a binding site for the protein of interest, or otherunrelated sequence. The differences in the nature and intensity of thecomplex formed in the presence of specific and nonspecific competitorallows identification of specific interactions.

Gel shift methods can include using, for example, colloidal forms ofCOOMASSIE (Imperial Chemicals Industries, Ltd) blue stain to detectproteins in gels such as polyacrylamide electrophoresis gels. Suchmethods are described, for example, in Neuhoff et al., Electrophoresis6:427-448 (1985), and Neuhoff et al., Electrophoresis 9:255-262 (1988),each of which is herein incorporated by reference in its entirety forteachings regarding gel shift methods. In addition to the conventionalprotein assay methods referenced above, a combination cleaning andprotein staining composition is described in U.S. Pat. No. 5,424,000,herein incorporated by reference in its entirety for its teachingregarding gel shift methods. The solutions can include phosphoric,sulfuric, and nitric acids, and Acid Violet dye.

Protein arrays are solid-phase ligand binding assay systems usingimmobilized proteins on surfaces which include glass, membranes,microtiter wells, mass spectrometer plates, and beads or otherparticles. The assays are highly parallel (multiplexed) and oftenminiaturized (microarrays, protein chips). Their advantages includebeing rapid and automatable, capable of high sensitivity, economical onreagents, and giving an abundance of data for a single experiment.Bioinformatics support is important; the data handling demandssophisticated software and data comparison analysis. However, thesoftware can be adapted from that used for DNA arrays, as can much ofthe hardware and detection systems.

One of the chief formats is the capture array, in which ligand-bindingreagents, which are usually antibodies but can also be alternativeprotein scaffolds, peptides or nucleic acid aptamers, are used to detecttarget molecules in mixtures such as plasma or tissue extracts. Indiagnostics, capture arrays can be used to carry out multipleimmunoassays in parallel, both testing for several analytes inindividual sera for example and testing many serum samplessimultaneously. In proteomics, capture arrays are used to quantitate andcompare the levels of proteins in different samples in health anddisease, i.e. protein expression profiling. Proteins other than specificligand binders are used in the array format for in vitro functionalinteraction screens such as protein-protein, protein-DNA, protein-drug,receptor-ligand, enzyme-substrate, etc. The capture reagents themselvesare selected and screened against many proteins, which can also be donein a multiplex array format against multiple protein targets.

For construction of arrays, sources of proteins include cell-basedexpression systems for recombinant proteins, purification from naturalsources, production in vitro by cell-free translation systems, andsynthetic methods for peptides. Many of these methods can be automatedfor high throughput production. For capture arrays and protein functionanalysis, it is important that proteins should be correctly folded andfunctional; this is not always the case, e.g. where recombinant proteinsare extracted from bacteria under denaturing conditions. Nevertheless,arrays of denatured proteins are useful in screening antibodies forcross-reactivity, identifying autoantibodies and selecting ligandbinding proteins.

Protein arrays have been designed as a miniaturization of familiarimmunoassay methods such as ELISA and dot blotting, often utilizingfluorescent readout, and facilitated by robotics and high throughputdetection systems to enable multiple assays to be carried out inparallel. Commonly used physical supports include glass slides, silicon,microwells, nitrocellulose or PVDF membranes, and magnetic and othermicrobeads. While microdrops of protein delivered onto planar surfacesare the most familiar format, alternative architectures include CDcentrifugation devices based on developments in microfluidics (Gyros,Monmouth Junction, N.J.) and specialized chip designs, such asengineered microchannels in a plate (e.g., The Living Chip™, Biotrove,Woburn, Mass.) and tiny 3D posts on a silicon surface (Zyomyx, HaywardCalif.). Particles in suspension can also be used as the basis ofarrays, providing they are coded for identification; systems includecolor coding for microbeads (Luminex, Austin, Tex.; Bio-RadLaboratories) and semiconductor nanocrystals (e.g., QDots™, Quantum Dot,Hayward, Calif.), and barcoding for beads (UltraPlex™, SmartBeadTechnologies Ltd, Babraham, Cambridge, UK) and multimetal microrods(e.g., Nanobarcodes™ particles, Nanoplex Technologies, Mountain View,Calif.). Beads can also be assembled into planar arrays on semiconductorchips (LEAPS technology, BioArray Solutions, Warren, N.J.).

Immobilization of proteins involves both the coupling reagent and thenature of the surface being coupled to. A good protein array supportsurface is chemically stable before and after the coupling procedures,allows good spot morphology, displays minimal nonspecific binding, doesnot contribute a background in detection systems, and is compatible withdifferent detection systems. The immobilization method used arereproducible, applicable to proteins of different properties (size,hydrophilic, hydrophobic), amenable to high throughput and automation,and compatible with retention of fully functional protein activity.Orientation of the surface-bound protein is recognized as an importantfactor in presenting it to ligand or substrate in an active state; forcapture arrays the most efficient binding results are obtained withorientated capture reagents, which generally require site-specificlabeling of the protein.

Both covalent and noncovalent methods of protein immobilization are usedand have various pros and cons. Passive adsorption to surfaces ismethodologically simple, but allows little quantitative or orientationalcontrol; it may or may not alter the functional properties of theprotein, and reproducibility and efficiency are variable. Covalentcoupling methods provide a stable linkage, can be applied to a range ofproteins and have good reproducibility; however, orientation may bevariable, chemical derivatization may alter the function of the proteinand requires a stable interactive surface. Biological capture methodsutilizing a tag on the protein provide a stable linkage and bind theprotein specifically and in reproducible orientation, but the biologicalreagent must first be immobilized adequately and the array may requirespecial handling and have variable stability.

Several immobilization chemistries and tags have been described forfabrication of protein arrays. Substrates for covalent attachmentinclude glass slides coated with amino- or aldehyde-containing silanereagents. In the Versalinx™ system (Prolinx, Bothell, Wash.) reversiblecovalent coupling is achieved by interaction between the proteinderivatised with phenyldiboronic acid, and salicylhydroxamic acidimmobilized on the support surface. This also has low background bindingand low intrinsic fluorescence and allows the immobilized proteins toretain function. Noncovalent binding of unmodified protein occurs withinporous structures such as HydroGel™ (PerkinElmer, Wellesley, Mass.),based on a 3-dimensional polyacrylamide gel; this substrate is reportedto give a particularly low background on glass microarrays, with a highcapacity and retention of protein function. Widely used biologicalcoupling methods are through biotin/streptavidin or hexahistidine/Niinteractions, having modified the protein appropriately. Biotin may beconjugated to a poly-lysine backbone immobilised on a surface such astitanium dioxide (Zyomyx) or tantalum pentoxide (Zeptosens, Witterswil,Switzerland).

Array fabrication methods include robotic contact printing, ink-jetting,piezoelectric spotting and photolithography. A number of commercialarrayers are available [e.g. Packard Biosciences] as well as manualequipment [V & P Scientific]. Bacterial colonies can be roboticallygridded onto PVDF membranes for induction of protein expression in situ.

At the limit of spot size and density are nanoarrays, with spots on thenanometer spatial scale, enabling thousands of reactions to be performedon a single chip less than 1 mm square. BioForce Laboratories havedeveloped nanoarrays with 1521 protein spots in 85 sq microns,equivalent to 25 million spots per sq cm, at the limit for opticaldetection; their readout methods are fluorescence and atomic forcemicroscopy (AFM).

Fluorescence labeling and detection methods are widely used. The sameinstrumentation as used for reading DNA microarrays is applicable toprotein arrays. For differential display, capture (e.g., antibody)arrays can be probed with fluorescently labeled proteins from twodifferent cell states, in which cell lysates are directly conjugatedwith different fluorophores (e.g. Cy-3, Cy-5) and mixed, such that thecolor acts as a readout for changes in target abundance. Fluorescentreadout sensitivity can be amplified 10-100 fold by tyramide signalamplification (TSA) (PerkinElmer Lifesciences). Planar waveguidetechnology (Zeptosens) enables ultrasensitive fluorescence detection,with the additional advantage of no intervening washing procedures. Highsensitivity can also be achieved with suspension beads and particles,using phycoerythrin as label (Luminex) or the properties ofsemiconductor nanocrystals (Quantum Dot). A number of novel alternativereadouts have been developed, especially in the commercial biotecharena. These include adaptations of surface plasmon resonance (HTSBiosystems, Intrinsic Bioprobes, Tempe, Ariz.), rolling circle DNAamplification (Molecular Staging, New Haven Conn.), mass spectrometry(Intrinsic Bioprobes; Ciphergen, Fremont, Calif.), resonance lightscattering (Genicon Sciences, San Diego, Calif.) and atomic forcemicroscopy [BioForce Laboratories].

Capture arrays form the basis of diagnostic chips and arrays forexpression profiling. They employ high affinity capture reagents, suchas conventional antibodies, single domains, engineered scaffolds,peptides or nucleic acid aptamers, to bind and detect specific targetligands in high throughput manner.

Antibody arrays have the required properties of specificity andacceptable background, and some are available commercially (BDBiosciences, San Jose, Calif.; Clontech, Mountain View, Calif.; BioRad;Sigma, St. Louis, Mo.). Antibodies for capture arrays are made either byconventional immunization (polyclonal sera and hybridomas), or asrecombinant fragments, usually expressed in E. coli, after selectionfrom phage or ribosome display libraries (Cambridge Antibody Technology,Cambridge, UK; BioInvent, Lund, Sweden; Affitech, Walnut Creek, Calif.;Biosite, San Diego, Calif.). In addition to the conventional antibodies,Fab and scFv fragments, single V-domains from camelids or engineeredhuman equivalents (Domantis, Waltham, Mass.) may also be useful inarrays.

The term “scaffold” refers to ligand-binding domains of proteins, whichare engineered into multiple variants capable of binding diverse targetmolecules with antibody-like properties of specificity and affinity. Thevariants can be produced in a genetic library format and selectedagainst individual targets by phage, bacterial or ribosome display. Suchligand-binding scaffolds or frameworks include ‘Affibodies’ based onStaph. aureus protein A (Affibody, Bromma, Sweden), ‘Trinectins’ basedon fibronectins (Phylos, Lexington, Mass.) and ‘Anticalins’ based on thelipocalin structure (Pieris Proteolab, Freising-Weihenstephan, Germany).These can be used on capture arrays in a similar fashion to antibodiesand may have advantages of robustness and ease of production.

An alternative to an array of capture molecules is one made through‘molecular imprinting’ technology, in which peptides (e.g., from theC-terminal regions of proteins) are used as templates to generatestructurally complementary, sequence-specific cavities in apolymerizable matrix; the cavities can then specifically capture(denatured) proteins that have the appropriate primary amino acidsequence (ProteinPrint™, Aspira Biosystems, Burlingame, Calif.).

Another methodology which can be used diagnostically and in expressionprofiling is the PROTEINCHIP® array (Ciphergen, Fremont, Calif.), inwhich solid phase chromatographic surfaces bind proteins with similarcharacteristics of charge or hydrophobicity from mixtures such as plasmaor tumour extracts, and SELDI-TOF mass spectrometry is used to detectionthe retained proteins.

Large-scale functional chips have been constructed by immobilizing largenumbers of purified proteins and used to assay a wide range ofbiochemical functions, such as protein interactions with other proteins,drug-target interactions, enzyme-substrates, etc. Generally they requirean expression library, cloned into E. coli, yeast or similar from whichthe expressed proteins are then purified, e.g. via a His tag, andimmobilized. Cell free protein transcription/translation is a viablealternative for synthesis of proteins which do not express well inbacterial or other in vivo systems.

For detecting protein-protein interactions, protein arrays can be invitro alternatives to the cell-based yeast two-hybrid system and may beuseful where the latter is deficient, such as interactions involvingsecreted proteins or proteins with disulphide bridges. High-throughputanalysis of biochemical activities on arrays has been described foryeast protein kinases and for various functions (protein-protein andprotein-lipid interactions) of the yeast proteome, where a largeproportion of all yeast open-reading frames was expressed andimmobilised on a microarray. Large-scale ‘proteome chips’ promise to bevery useful in identification of functional interactions, drugscreening, etc. (Proteometrix, Branford, Conn.).

As a two-dimensional display of individual elements, a protein array canbe used to screen phage or ribosome display libraries, in order toselect specific binding partners, including antibodies, syntheticscaffolds, peptides and aptamers. In this way, ‘library against library’screening can be carried out. Screening of drug candidates incombinatorial chemical libraries against an array of protein targetsidentified from genome projects is another application of the approach.

A multiplexed bead assay, such as, for example, the BD™ Cytometric BeadArray, is a series of spectrally discrete particles that can be used tocapture and quantitate soluble analytes. The analyte is then measured bydetection of a fluorescence-based emission and flow cytometric analysis.Multiplexed bead assay generates data that is comparable to ELISA basedassays, but in a “multiplexed” or simultaneous fashion. Concentration ofunknowns is calculated for the cytometric bead array as with anysandwich format assay, i.e. through the use of known standards andplotting unknowns against a standard curve. Further, multiplexed beadassay allows quantification of soluble analytes in samples neverpreviously considered due to sample volume limitations. In addition tothe quantitative data, powerful visual images can be generated revealingunique profiles or signatures that provide the user with additionalinformation at a glance.

The methods disclosed herein comprise assessing/measuring the efficacyor sufficiency of an immune response to a selected antigen in a subject.The disclosed methods utilize tissue samples from the subject to providethe basis for assessment. Such tissue samples can include, but are notlimited to, blood (including peripheral blood and peripheral bloodmononuclear cells), tissue biopsy samples (e.g., spleen, liver, bonemarrow, thymus, lung, kidney, brain, salivary glands, skin, lymph nodes,and intestinal tract), and specimens acquired by pulmonary lavage (e.g.,bronchoalveolar lavage (BAL)). Thus it is understood that the tissuesample can be from both lymphoid and non-lymphoid tissue. Examples ofnon-lymphoid tissue include but are not limited to lung, liver, kidney,and gut. Lymphoid tissue includes both primary and secondary lymphoidorgans such as the spleen, bone marrow, thymus, and lymph nodes.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how thecompounds, compositions, articles, devices, and/or methods described andclaimed herein are made and evaluated, and are intended to be purelyexemplary and are not intended to limit the scope of what the inventorsregard as their invention. Efforts have been made to ensure accuracywith respect to numbers (e.g., amounts, temperature, etc.) but someerrors and deviations should be accounted for. Unless indicatedotherwise, parts are parts by weight, temperature is in ° C. or is atambient temperature, and pressure is at or near atmospheric. There arenumerous variations and combinations of reaction conditions, e.g.,component concentrations, desired solvents, solvent mixtures,temperatures, pressures and other reaction ranges and conditions thatcan be used to optimize the product purity and yield obtained from thedescribed process. Only reasonable and routine experimentation will berequired to optimize such process conditions.

Example 1: Mosaic Virus-Like-Particle Vaccine Protects Against Classicand Variant Infectious Bursal Disease Viruses

Nucleotide sequences that encode the pVP2 proteins from a variant IBDVstrain designated USA08MD34p and a classic IBDV strain designated Mo195were produced using RT-PCR and cloned into a pGEM-T Easy vector. Anucleotide sequence that encodes the VP3 protein was also produced fromthe USA08MD34p viral genome using RT-PCR and cloned into a pGEM-T Easyvector. The VP3 and pVP2 clones were inserted into the pVL1393Baculovirus transfer vector and sequenced to confirm their orientationto the promoter and to insure they contained uninterruptedopen-reading-frames. Recombinant Baculoviruses were constructed bytransfection in Sf9 cells. Three recombinant Baculoviruses were producedand contained the USA08MD34p-VP3, USA08MD34p-pVP2 or Mo195-pVP2 genomicsequences. Virus-like particles (VLPs) were observed using transmissionelectron microscopy when the USA08MD34p-VP3 Baculovirus wasco-inoculated into Sf9 cells with either of the pVP2 constructs. VLPswere also observed when the USA08MD34p-pVP2 and Mo195-pVP2 wereco-expressed with USA08MD34p-VP3. These mosaic VLPs contained bothclassic and variant pVP2s. The USA08MD34p, Mo195 and mosaic VLPs wereused to vaccinate chickens. They induced an IBDV specific antibodyresponse that was detected by ELISA and virus-neutralizing antibodieswere detected in vitro. Chickens vaccinated with the mosaic VLPs wereprotected from a virulent variant IBDV strain (V1) and a virulentclassic IBDV strain (STC). The results indicate the mosaic VLPsmaintained the antigenic integrity of the variant and classic virusesand have the potential to serve as a multivalent vaccine for use inbreeder flock.

Materials and Methods

Viruses

The IBDV variant strain USA08MD34p (GenBank Accession #GQ856676) wasused to obtain pVP2 and VP3 sequences. The IBDV variant strainUSA08MD34p was isolated from a Maryland broiler flock in 2008 (Jackwood2010). The IBDV used to obtain the classic pVP2 sequences was Mo195(GenBank Accession #AY780324). It was isolated from a Missouri broilerflock in 2004 (Jackwood 2005). The STC and V1 IBDV strains were used tochallenge vaccinated specific-pathogen-free (SPF) chickens (CharlesRiver Laboratories, North Franklin, Conn.). The V1 variant virus(GenBank Accession #AF281235) is pathogenic in SPF chickens and itsamino acid sequence across the four P domains of VP2 is identical toDel-E (Jackwood 2001). The STC strain (GenBank Accession #D00499) is theclassic standard challenge virus from the U.S. Animal and Plant HealthInspection Service (APHIS), National Veterinary Services Laboratory(Kibenge 1990).

Preparation of IBDV Gene Clones

The VP3 from IBDV strain USA08MD34p (variant strain) was amplified usinga reverse transcriptase—polymerase chain reaction (RT-PCR) kit(SuperScript III One-step RT-PCR, Invitrogen, Life Technologies, GrandIsland, N.Y.). The primers VP3F: 5′-GTACCTGATCACCATGGCTGCATCAGAGTTC-3′(SEQ ID NO: 1) and

VP3R: 5′-CAGGATGATCACTCAAGGTCCTCATCAGAG-3′ (SEQ ID NO: 2) amplified theentire VP3 sequence from base 2,323 to base 3,123 of genome segment A.The start codon (ATG) in the forward primer is listed in italics and theunderlined sequences are a genetic marker (not IBDV sequence) designedto identify the cloned gene.

The pVP2 portion of genome segment A was amplified from both theUSA08MD34p and Mo195 viruses using a RT-PCR kit (SuperScript IIIOne-step RT-PCR, Invitrogen) and the following primers: VP2F:5′-TTCGATGATCACGATGACAAACCTGTCAGATC-3′ (SEQ ID NO: 3) and VP2R:5′-ACTACTGATCACCCCTTGTCGGCGGCGAGAG-3′ (SEQ ID NO: 4). The start codon(ATG) in the forward primer is listed in italics and the underlinedsequences are a genetic marker (not IBDV sequence) designed to identifythe cloned gene. These primers amplify the entire pVP2 sequence frombase 64 to base 1,635 of genome segment A.

For both the VP3 and pVP2 reactions the RT was at 55° C. for 45 minwhich was followed by 2 min denaturation at 95° C. The 40 PCR cyclesconsisted of 95° C. for 15 sec, 55° C. for 30 sec and 68° C. for 3.5min. A 7 min hold at 68° C. was added to the end of the assay.

The 801 bp VP3 RT-PCR product and the 1,572 bp pVP2 RT-PCR products wereligated into the pGEM-T Easy vector (Promega Corp., Madison Wis.) usinga Rapid Ligation Kit (Promega Corp.). Incubation for the ligationreaction was overnight at 4° C. The plasmids were then used to transformthe E. coli strain HB-101 (Promega Corp.). The transformed bacteria weregrown on L-agar containing 100 μg/ml ampicillin, 100 μg/ml X-gal and 0.1μM IPTG at 37° C. overnight. White colonies were selected and grownovernight with shaking at 37° C. in 4.0 ml L-Broth containing 100 μg/mlampicillin. The plasmids were extracted from 1.0 ml of the brothcultures using a Wizard Plus SV Minipreps DNA Purification System(Promega Corp.). Inserts were excised from the plasmids using EcoRI(Promega Corp.) and visualized on a 0.8% agarose gel.

Construction of Baculovirus Transfection Vectors

The pVL1393 baculovirus transfection vector (BD Biosciences, San Jose,Calif.) was used. The vector was linearized using EcoRI and then treatedwith 0.05 U Calf Intestinal Alkaline Phosphatase (Promega Corp.) at 37°C. for 1 hr. The reaction was stopped by adding 300 μl of a 20% SDSsolution and the vector was phenol/chloroform extracted and ethanolprecipitated with a 0.5 volume of 7.5M Ammonium Acetate (Sigma ChemicalCo.).

The VP3 and pVP2 inserts that were excised from the pGEM-T Easy vectorswere ligated into the linear pVL1393 vector using a Rapid Ligation Kit(Promega Corp.). Incubation was for 12 hours at 4° C. and the plasmidswere then used to transform the E. coli strain HB-101 (Promega Corp.).The bacteria were placed onto L-agar containing 100 μg/ml ampicillin andincubated at 37° C. overnight. Bacterial colonies that grew on the agarplates were selected and grown in 4.0 ml L-Broth containing 100 μg/mlampicillin at 37° C. with shaking overnight. The plasmids were extractedfrom a 1.0 ml volume of the bacterial cultures using a Wizard Plus SVMinipreps DNA Purification System (Promega Corp.).

To determine the orientation of the VP3 and pVP2 inserts in the pVL1393plasmid, the constructs were cut with the restriction enzyme PstI andthe fragments were visualized on a 0.8% agarose gel.

Transfection of Sf9 Insect Cells

The pVL1393 constructs containing VP3s and pVP2s in the correctorientation were used to transfect Sf9 insect cells. The BD BaculoGoldTransfection Kit (BD Biosciences) was used. Briefly, the cell culturemedium was removed from Sf9 cells growing in 6-well culture plates(Becton Dickinson Labware, Franklin Lakes, N.J.) and 1.0 ml ofTransfection Buffer A was added to each of the 6 wells. Approximately2.0 μg of each pVL1393 construct was added to 0.5 μg of the linearizedBaculovirus DNA supplied in the BaculoGold kit. After a 5 min incubationat room temperature, 1.0 ml of Transfection Buffer B was added and thesolution was gently agitated. This DNA mixture was then added slowly tothe Sf9 cells and incubated at 27° C. for 4 hrs. Following thisincubation, the transfection solution was removed from the cells and 3.0ml of TNM-FH medium (BD-Biosciences) was gently added. Incubationcontinued at 27° C. for 4 days. The supernatants were then removed andhalf was stored at −70° C. until they could be examined for VP3 and pVP2expression products while the other half was stored at 4° C. until theywere used to inoculate new Sf9 cell cultures.

Detection of VP3 and pVP2 Nucleotide Sequences in RecombinantBaculoviruses

To determine if the transfections were successful, media from thetransfected Sf9 cells were examined using PCR for the presence of VP3and pVP2 nucleotide sequences in the recombinant Baculoviruses. Theprimers used for the VP3 sequences were the same as those used forcloning. For detection of the pVP2 sequences, a 743-bp segment of thehypervariable region of VP2 (hvVP2) from nucleotides 737 to 1479 wasamplified using primers 743-1 (5′-GCCCAGAGTCTACACCAT-3′) (SEQ ID NO: 5)and 743-2 (5′-CCCGGATTATGTCTTTGA-3′) (SEQ ID NO: 6) (Jackwood 2005).

Detection of pVP2 and Virus-Like Particle (VLP) Expression Products

The pVP2 protein was generated by infecting Sf9 cells with either theUSA08MD34p-pVP2 baculovirus construct or the Mo195-pVP2 construct. TheVLPs were prepared by inoculating Sf9 cells with the pVP2 constructsplus the USA08MD34p-VP3 baculovirus construct. Expression of the pVP2proteins and VLPs was examined using an antigen-capture (AC)-ELISA(Synbiotics Corp., Kansas City, Mo.). The AC-ELISA plate contained theIBD screening monoclonal antibodies B69, R63 and #10. These monoclonalantibodies were reported to bind classic and variant VP2 proteins(Vakharia 1994). Supernatants from recombinant Baculovirus infected Sf9cells were tested undiluted and at the following dilutions: 1:2, 1:4,1:8, 1:16 and 1:64.

Visualization of VLPs

Transmission electron microscopy was used to determine the structuralintegrity of the VLPs expressed from Sf9 cells infected with theUSA08MD34p-pVP2/USA08MD34p-VP3, Mo195-pVP2/USA08MD34p-VP3 and mosaicUSA08MD34p-pVP2/Mo195-pVP2/USA08MD34p-VP3 combinations. Supernatantsfrom the cell cultures were harvested 4 days post-inoculation. They werefrozen and thawed once, clarified using slow speed centrifugation andthen layered over 1.0 ml of a 20% sucrose solution in a 14×89 mmultracentrifuge tube (Beckman, Palo Alto, Calif.). The samples werepelleted though the sucrose cushion in an ultracentrifuge at 150,000×gfor 3 hrs. The pellets were rinsed with sterile H₂O and then suspendedin a 1.0 ml volume of sterile H₂O before being stored at −70° C. A 25 μlvolume of each VLP was place in an eppendorf tube and particulates werepelleted at 16,000×g for 2 min. The supernatants were then placed onformvar coated grids and stained with uranyl acetate for 2 min in thedark. Samples were examined using a transmission electron microscope(Hitachi H-7500) for VLPs.

Vaccination of Chickens with VLPs and Challenge

The VLPs were used to vaccinate 3 week old SPF chickens. The birds werebled prior to being vaccinated and were negative for IBDV antibodies.They were vaccinated with a 0.1 ml dose of the Sf9 cell culturescontaining the USA08MD34p, Mo195 or mosaic VLPs. Inoculations were viathe intramuscular route. Two weeks later, they were vaccinated with asecond 0.1 ml dose of the same VLP samples via the subcutaneous route.The birds were then bled two weeks following the booster vaccination andthe sera were examined for IBDV specific antibodies using an IBDxr ELISAkit (IDEXX, Corp.). The sera were also examined for virus-neutralizing(VN) antibody titers using a standard protocol and classic (S706) andvariant (Del-E) antigens (Dybing 1998).

Two weeks following the booster vaccination, twenty birds that werevaccinated using the mosaic VLPs were allotted into 2 groups of tenbirds each. One group was challenged with 10² chick infectious doses(CID)₅₀ of the STC virus and the other with the same dose of the variantV1 strain of IBDV. Two groups of 6 SPF birds each that had not beenvaccinated were also challenged with either the STC or V1 strains. Afifth group of 5 SPF birds served as non-vaccinated and non-challengedcontrols. At seven days following challenge all birds in the five groupswere euthanized and examined for gross lesions in the bursa. The bursaand body weights of each bird were recorded.

Statistics

The bursa and body weights recorded at necropsy were used to calculate abursa/body weight ratio (B/BW). Bursa/body weight (B/BW) ratios werecalculated as the bursa weight (g)/body weight (g)×1000. These B/BWratios were compared for statistical differences among the groups usingthe SAS: Proc GLM program.

Results

Cloning the pVP2 and VP3 Sequences

The RT-PCR products USA08MD34p-pVP2, Mo195-pVP2 and USA08MD34p-VP3 wereligated into the pGEM-T Easy vector and used to transform E. coli HB101cells. White colonies were selected from the agar plates and examinedfor plasmids and IBDV sequences. The restriction enzyme EcoRI was usedbecause it excises the IBDV sequences from the plasmid. The presence of1,572 bp pVP2 inserts and 801 bp VP3 inserts were observed using agargel electorphoresis (FIG. 1).

Insertion of the pVP2 and VP3 Clones into the Baculovirus TransferVector

The pVL1393 Baculovirus transfer vector was used to insert the pVP2 andVP3 clones into the Baculovirus genome. The pVP2 and VP3 inserts fromthe pGEM-T Easy vectors were excised using EcoRI and purified on anagarose gel (FIG. 2). The inserts were then ligated into the pVL1393plasmid that was cut with EcoRI and dephosphorlated. The resultingplasmids were used to transform E. coli HB-101 cells and then examinedfor IBDV sequences using the EcoRI enzyme and agarose gelelectrophoresis (FIG. 3).

To express the pVP2 and VP3 sequences they must be downstream from theBaculovirus polyhedron promoter and in the correct direction. Becausethe pVL1393 vector was cut with one restriction enzyme, the pVP2 and VP3clones could have been ligated into this vector in either direction. Theorientation of the pVP2 inserts in the pVL1393 vector was determinedusing the enzyme PstI. This enzyme was selected because it cuts once inthe plasmid and has multiple cut sites in the inserts. The pVP2 clonesin the correct direction produce bands at 1,011 bp, 332 bp and 74 bpafter digestion with PstI. Similarly the VP3 clones were cut with BglIIto determine if they were in the correct orientation. This enzymeproduces a band at 155 bp if the VP3 insert was ligated into the plasmidin the correct direction. The pVL1393 pVP2 and VP3 constructs in thecorrect direction were selected for Transfection into the Baculovirusgenome. These constructs were also RT-PCR amplified and sequenced toinsure they were in the correct orientation and contained uninterruptedopen reading frames.

Transfection and Propagation of Recombinant Baculoviruses

The Sf9 cells and cell culture media were harvested 4 days followingtransfection of the pVP2 and VP3 sequences into the baculovirus genome.The samples were stored at 4° C. and then used to inoculate new culturesof Sf9 cells. Cytopathic effects (CPE) that consisted of floating cellsand holes in the monolayer were observed at 3 and 4 dayspost-inoculation. Samples for protein expression were collected at 4days post-inoculation and frozen at −70° C. Samples for furtherpropagation of the recombinant Baculoviruses were collected at 4 dayspost-inoculation and stored at 4° C.

Using RT-PCR the pVP2 and VP3 nucleotide sequences were detected in theinfected Sf9 cell cultures. To determine if the pVP2 proteins were beingexpressed the samples were tested in the AC-ELISA. The monoclonalantibodies on the AC-ELISA plate (Synbiotics) were reported to bindclassic and variant viruses. The optical density readings for thesamples tested are shown in Table 1. The amino acids and nucleicsequence of the proteins and nucleotides sent forth in Table 1 are inSEQ ID NOS. 7-12:

TABLE 1 Description SEQ ID NOs Variant Virus pp34 VP3 Nucleotide SEQ IDNO: 7 Sequence Variant Virus pp34 VP3 Amino Acid SEQ ID NO: 8 SequenceVariant Virus pp34 pVP2 Nucleotide SEQ ID NO: 9 Sequence Variant Viruspp34 pVP2 Amino Acid SEQ ID NO: 10 Sequence Classic Virus Mo195 pVP2Nucleotide SEQ ID NO: 11 Sequence Classic Virus Mo195 pVP2 Amino AcidSEQ ID NO: 12 Sequence

The results indicate the Mo195-pVP2 construct was expressing thisprotein. The USA08MD34p-pVP2 and USA08MD34p-VP3 constructs were negativein the AC-ELISA. The negative USA08MD34p-VP3 result was expected sincemonoclonal antibodies B69, R63 and #10 do not bind this protein.

Because the AC-ELISA results for the first USA08MD34p-pVP2 Baculovirusconstruct were negative, a second Baculovirus construct was preparedfrom a different clone and tested in the RT-PCR assay. This newUSA08MD34p-pVP2 Baculovirus was positive in the RT-PCR assay. However,when it was tested for expression of pVP2 using the AC-ELISA the resultswere also negative. Since it is possible the AC-ELISA monoclonalantibodies do not bind the USA08MD34p-pVP2 protein, this secondconstruct was used in subsequent experiments to produce virus-likeparticles (VLPs).

Production of Virus-Like Particles (VLPs)

The production of VLPs was initiated by inoculating monolayers of Sf9cells with the USA08MD34p-VP3 Baculovirus. These cell cultures were theninoculated with either the USA08MD34p-pVP2 or Mo195-pVP2 Baculoviruses.After 4 days of incubation at 27° C. the cultures were observed to haveCPE and they were frozen at −70° C. The USA08MD34p-pVP2/VP3 andMo195-pVP2/VP3 cultures were tested in the AC-ELISA for proteinexpression (Table 2). The optical density readings for the Mo195 VLPswere strongly positive. The USA08MD34p VLPs were also positive in theAC-ELISA, showing the monoclonal antibodies do not bind theUSA08MD34p-pVP2 but they do bind the USA08MD34p proteins when the pVP2is combined with VP3 into a VLP.

The Mo195 and USA08MD34p VLPs were examined using electron microscopyfor the presence of particles that resembled IBDV. Both culturescontained numerous IBDV like particles (VLPs) (FIG. 4) and theun-inoculated control Sf9 cultures were negative for VLPs. The VLPsvaried in size from 40 nm to 80 nm but most were approximately 60 nm.

TABLE 2 AC-ELISA and assays for antibody titers to VLPs. AC- ELISA ELISAVN Antibody Optical Antibody titers³ Construct Density¹ titers² VariantClassic USA08MD34p-pVP2 0.231 NA NA NA Mo195-pVP2 0.640 NA NA NAUSA08MD34p-VP3 0.116 NA NA NA Sf9 Negative Control⁴ 0.241 NA NA NAUSA08MD34p-VLP 0.797 2,042 150 <50 Mo195-VLP 1.379 9,130 <50 1,200Mosaic VLP⁵ ND 1,254 229 185 Sf9 Negative Control 0.375 0 <50 <50¹AC-ELISA optical density >0.600 = positive, 0.300-0.600 = suspectpositive, <0.300 = negative (Synbiotics, Corp. Technical Insert). ND =Not determined. ²The IDEXX IBD-XR assay was used. NA = Not applicable.Antisera were only prepared in chickens to the VLP constructs. ³The VNtiters were only determined for VLP samples. The cell culture adaptedviruses used were Del-E for the variant antigen and S706 for the classicantigen. ⁴The negative controls consisted of non-inoculated Sf9 cellcultures. ⁵The mosaic VLPs contained VP2 from both the USA08MD34p andMo195 strains.

The Mo195-VP2, USA08MD34p-VP2 and USA08MD34p-VP3 were inoculated intoSf9 cells to produce VLPs containing both classic and variant pVP2antigens. The resulting mosaic VLPs resembled the capsid structure ofIBDV (FIG. 4).

Serology and Challenge Experiment

The Mo195, USA08MD34p and mosaic VLPs were used to vaccinate SPFchickens. The three-week-old SPF birds were negative for IBDV antibodiesprior to being vaccinated. Two weeks following booster vaccination usingeither USA08MD34p, Mo195 or mosaic VLPs, the sera from vaccinated birdswere positive in the ELISA and VN assays. The ELISA antibody titers toIBDV and the virus-neutralization (VN) antibody titers are reported inTable 2. The USA08MD34p and Mo195 VLPs were immunogenic in chickens andproduced IBDV specific antibodies detected in the ELISA. The VN dataindicate the antibodies produced were capable of neutralizing IBDVstrains in cell culture. The Mo195-VLP antisera neutralized S706 (meantiter=1,200). When these sera were tested using the Del-E antigen theneutralizing titer was negative. The USA08MD34p-VLP antisera neutralizedthe Del-E antigen but the titer was low (mean titer=150). When thesesera were tested against the S706 antigen, no neutralizing antibodieswere detected. The mosaic VLPs containing VP2 from both USA08MD34p andMo195 produced ELISA titers and neutralizing antibodies to both theclassic (S706) and variant (Del-E) IBDV strains (Table 2).

The mean VN titers to both variant and classic antigens were relativelylow compared to the mean ELISA titer for these mosaic VLPs however,challenge of these birds with the classic STC or variant V1 strainsindicated they were protected (Table 3). The STC challenge virusproduced gross lesions in the bursas of all 6 birds in thenon-vaccinated STC control group. This was not evident in the B/BWratios of this group since STC typically causes an enlarged edematousbursa prior to atrophy. The six V1 challenged birds in the V1 controlgroup all had small friable bursas typical of this variant virus. Theirmean B/BW ratios were significantly different (p<0.05) compared to thenon-vaccinated and non-challenged controls. No gross lesions wereobserved in the bursas of mosaic VLP vaccinated birds challenged withSTC. One of the ten birds in the mosaic VLP vaccinated group that waschallenged with V1 had a small bursa typical of a variant virusinfection. The bursas of the other nine birds in this group appearednormal. The mean B/BW ratios of birds in the mosaic VLP vaccinated andchallenged groups were not statistically different from thenon-vaccinated, non-challenged controls (Table 3).

TABLE 3 Necropsy results of mosaic VLP vaccinated birds followingchallenge. Group Challenge Virus¹ Lesions² Bursa/Body wt Ratios³ ControlNone 0/5 4.71 ± 0.71^(a) STC Control STC 6/6 4.40 ± 0.77^(a) V1 ControlV1 6/6 1.86 ± 0.37^(b) Mosaic VLP⁴ STC  0/10 4.54 ± 0.95^(a) Mosaic VLPV1  1/10 3.67 ± 1.22^(a) ¹The challenge viruses were given at 10^(2.0)CID₅₀/bird. The birds were challenged 7 days following the last boostervaccination. ²Number of birds with gross lesions in the bursa/totalnumber of birds in the group. ³Bursa/body weight ratios ± standarddeviation. ⁴The mosaic VLPs contained VP2 from both the USA08MD34p andMo195 strains.Discussion

As described herein, the Baculovirus expression system was used tocreate an alternative to bursa derived IBDV antigens that can be used inbreeder flock vaccines.

The molecular expression of IBDV proteins that are immunogenic has beenreported but these subunit proteins have not been successfullyintegrated into an efficacious vaccine for IBD (Dybing 1998; Vakharia1997; Vakharia 1994; Pitcovski 1996; Martinez 2000). As shown herein,pVP2s from a variant and a classic IBDV were co-expressed with VP3 in aBaculovirus system to produce VLPs. This differs from previous studiesin that the Baculovirus expressed pVP2 from the variant and classicviruses were incorporated into a mosaic VLP product containing bothantigenic types of the viral protein.

The USA08MD34p and Mo195 represent variant and classic virusesrespectively. The pVP2 expression products from the Mo195 virus testedpositive in the AC-ELISA but the pVP2 from USA08MD34p was negative inthis assay. This result was surprising since the co-expression ofUSA08MD34p-VP2 With USA08MD34p-VP3 produced VLPs that were detected inthe AC-ELISA and by electron microscopy. Furthermore, inoculation of theUSA08MD34p VLPs in chicks produced anti-IBDV antibodies. The AC-ELISAscreening plate (Synbiotics, Corp) contains the monoclonal antibodiesR63, B69 and #10. The reactivity of these monoclonal antibodies withclassic and variant IBDV strains indicates they should be useful indetecting both antigenic types of the virus (Vakharia 1994). All threemonoclonal antibodies map to the P domain of VP2 but individually, R63,B69 and #10 do not detect all IBDV strains (Vakharia 1994; Letzel 2007).Substitution mutations in the USA08MD34p virus may have altered theepitopes such that these monoclonal antibodies were unable to bind theBaculovirus expressed USA08MD34p-VP2. Detection of the USA08MD34p VLP inthe AC-ELISA indicates one or more of the monoclonal antibodies bind atertiary epitope formed by the pVP2 trimer or an epitope was hidden whenthe VP2 was singularly expressed but exposed when it was co-expressedwith VP3. The result shows that VLP capsid structures are higher qualityantigens than VP2 tubules and polyprotein derived mixed structures(Martinez 2003).

Specific antibodies to IBDV were detected by the ELISA in serum samplesfrom chickens vaccinated with all the VLP constructs. The ELISA cannotdistinguish between antibodies to variant and classic viruses. Using aDel-E variant virus and an S706 classic virus adapted to replicate incell culture, the serum samples were examined in vitro for variant andclassic specific neutralizing antibodies.

When the mosaic VLPs contained pVP2 from both USA08MD34p and Mo195,neutralizing antibodies to both the Del-E and S706 antigens wereobserved. The result indicates both classic and variant pVP2 expressionproducts were incorporated into the VLP vaccine. Not only was theantigenic integrity maintained but the immunity induced by the mosaicVLPs protected chickens against pathogenic classic (STC) and variant(V1) IBDV strains. Furthermore, these mosaic VLPs have the ability toinduce maternal immunity that protects progeny chicks from pathogenicvariant and classic viruses.

Example 2: The Use of ELISA as a Diagnostic

Antigen for coating ELISA plates was prepared by infecting SF9 insectcells with a combination of recombinant Baculoviruses expressing pVP2and VP3. The infected cells produced VLPs and were harvested 4 daysfollowing infection. The VLPs were diluted 1:5 in PBS (1.9 mM NaH2P04,8.1 mM Na2HP04, 154 mM NaCl (pH7.2]) containing 0.05% (wt/vol) sodiumazide and used to coat 96-well flat-bottom plates (Falcon; BectonDickinson, Lincoln Park, N.J.). This dilution of antigen was determinedto be optimal using standard procedures. A 50 ul volume of the dilutedVLP antigen was used to coat each well of a 96-well plate for 24 hrs atroom temperature. The antigen-coated 96-well plates were washed threetimes in water and then incubated at room temperature for 30 min inblocking buffer (170 mM″H3B04 [pH 8.5], 120 mM NaCl, 1 mM EDTA, 0.05%[wt/vol] sodium azide, 0.25% [wt/vol] bovine serum albumin, 0.05%[vol/vol] Tween 20). After three washes in water, a 50 ul volume ofserum diluted in blocking buffer was added to each well. Incubationcontinued at room temperature for 30 min. The ELISA plates were thenwashed three times in water, once for 10 min in blocking buffer, andthen three times in water. A horseradish peroxidase-labeled goatanti-chicken immunoglobulin G was used according to the manufacturer'sdirections. A 50 ul volume was added to each well. Plates were incubatedat room temperature for 30 min and then washed in water, in blockingbuffer, and again in water as described above. A 75 ul volume of thesubstrate was added, and after 15 min the color development was stoppedwith 5% (wt/vol) SDS in water. Test wells were read on an ELISA readerat a wavelength of 620 nm.

The VLP antigens reacted with the serum antibodies to IBDV and produceda positive result in the ELISA. Chicken serum samples from birds notexposed to IBDV were negative in the assay. The results indicate thatVLP antigens can be used in the ELISA to detect antibodies to IBDVstrains.

Example 3: Breeder Vaccination and Progeny Challenge Study for VeryVirulent Strain

The VLP vaccine for vvIBDV can be used to produce maternal immunity inchickens. The VLP vvIBDV vaccine can be added to an existing commercialproduct designed for breeder bird vaccination or can be used alone. Totest the efficacy of such a vaccine, breeder birds are vaccinated andtheir progeny are tested for immunity to a vvIBDV challenge strain.

1. Vaccines: Commercial Killed Breeder vaccine

Commercial Killed Breeder vaccine with vvIBDV-VLP

2. Experimental Design:

1. Divide the Broiler Breeders into two groups. One group is vaccinatedwith the Commercial Killed Breeder vaccine and another is given the samevaccine with the vvIBDV-VLP added. A third group receives only thevvIBDV VLP vaccine and a fourth group contains non-vaccinated controlbreeder birds.

2. Collect fertile eggs and hatch chicks

3. Test chicks for antibodies to IBDV using the ELISA orvirus-neutralization assays.

4. Challenge chicks at 1, 2 and 3 weeks of age with vvIBDV to assess thematernal immunity to this virus.

5. Necropsy chicks one-week following challenge and determine the grossand histopathologic lesions. Test the bursa tissues for the presence ofvvIBDV using molecular techniques.

It will be apparent to those skilled in the art that variousmodifications and variations can be made in the present inventionwithout departing from the scope or spirit of the invention. Otheraspects of the invention will be apparent to those skilled in the artfrom consideration of the specification and practice of the inventiondisclosed herein. It is intended that the specification and examples beconsidered as exemplary only, with a true scope and spirit of theinvention being indicated by the following claims.

REFERENCES

-   [1] Dobos P, Hill B, Hallett R, Kells D, Becht H, Teninges D.    Biophysical and Biochemical Characterization of Five Animal Viruses    with Bisegmented Double-Stranded RNA Genomes. J Virol 1979;    32:593-605.-   [2] von Einem U I, Gorbalenya A E, Schirrmeier H, Behrens S E,    Letzel T, Mundt E. VP1 of infectious bursal disease virus is an    RNA-dependent RNA polymerase. J Gen Virol 2004; 85:2221-9.-   [3] Birghan C, Mundt E, Gorbalenya A E. A non-canonical Lon    proteinase lacking the ATPase domain employs the Ser-Lys catalytic    dyad to exercise broad control over the life cycle of a    double-stranded RNA virus. EMBO Journal 2000; 19:114-23.-   [4] Kibenge F S B, Dhillon A S, Russell R G. Biochemistry and    Immunology of Infectious Bursal Disease Virus. J Gen Virol 1988;    69:1757-75.-   [5] Galloux M, Libersou S, Morellet N, et al. Infectious Bursal    Disease Virus, a Non-enveloped Viurs, Possesses a Capsid-associated    Peptide that Deforms and Perforates Biological Membranes. J    Biological Chemistry 2007; 282:20774-84.-   [6] Coulibaly F, Chevalier C, Delmas B, Rey F A. Crystal structure    of an aquabirnavirus particle: Insights into antigenic diversity and    virulence determinism. J Virol 2010; 84:1792-9.-   [7] Coulibaly F, Chevalier C, Gutsche I, et al. The Birnavirus    crystal structure reveals structural relationships among icosahedral    viruses. Cell 2005; 120:761-72.-   [8] Caston J R, Martinez-Torrecuadrada J L, Maraver A, Lombardo E,    Rodriguez J F. C terminus of infectious bursal disease virus major    capsid protein VP2 is involved in definition of the T number for    capsid assembly. J Virol 2001; 75(22):10815-28.-   [9] Maraver A, Clemente R, Rodriguez J F, Lombardo E. Identification    and Molecular Characterization of the RNA Polymerase-Binding Motif    of Infectious Bursal Disease Virus Inner Capsid Protein VP3. J Virol    2003; 77, No. 4:2459-68.-   [10] Lombardo E, Maraver A, Caston J R, et al. VP1, the putative    RNA-dependent RNA polymerase of infectious bursal disease virus,    forms complexes with the capsid protein VP3, leading to efficient    encapsidation into virus-like particles. J Virol 1999; 73:6973-83.-   [11] Martinez-Torrecuadrada J L, Caston J R, Castro M, Carrascosa J    L, Rodriguez J F, Casal J I. Different Architectures in the Assembly    of Infectious Bursal Disease Virus Capsid Proteins Expressed in    Insect Cells. Virology 2000; 278:322-31.-   [12] Ona A, Luque D, Abaitua F, Maraver A, Caston J R, Rodriguez    J F. The C-terminal domain of the pVP2 precursor is essential for    the interaction between VP2 and VP3, the capsid polypeptides of    infectious bursal disease virus. Virology 2004; 322:135-42.-   [13] Heine H G, Haritou M, Failla P, Fahey K, Azad A A. Sequence    analysis and expression of the host-protective immunogen VP2 of a    variant strain of infectious bursal disease virus which can    circumvent vaccination with standard type I strains. J Gen Virol    1991; 72:1835-43.-   [14] Eterradossi N, Toquin D, Rivallan G, Guittet M. Modified    activity of a VP2-located neutralizing epitope on various vaccine,    pathogenic and hypervirulent strains of infectious bursal disease    virus. Arch Virol 1997; 142:255-70.-   [15] Eterradossi N, Arnauld C, Toquin D, Rivallan G. Critical amino    acid changes in VP2 variable domain are associated with typical and    atypical antigenicity in very virulent infectious bursal disease    viruses. Arch Virol 1998; 143:1627-36.-   [16] Vakharia V N, He J, Ahamed B, Snyder D B. Molecular basis of    antigenic variation in infectious bursal disease virus. Virus Res    1994; 31:265-73.-   [17] Letzel T, Coulibaly F, Rey F A, et al. Molecular and structural    bases for the antigenicity of VP2 of infectious bursal disease    virus. J Virol 2007; 81:12827-35.-   [18] Schnitzler D, Bernstein F, Muller H, Becht H. The genetic basis    for the antigenicity of the VP2 protein of the infectious bursal    disease virus. J Gen Virol 1993; 74:1563-71.-   [19] Jackwood D J, Sommer-Wagner S E. Amino acids contributing to    antigenic drift in the infectious bursal disease Birnavirus (IBDV).    Virology 2011; 409:33-7.-   [20] Jackwood D J, Sommer-Wagner S E. Detection and characterization    of infectious bursal disease viruses in broilers at processing.    Preventive Veterinary Medicine 2010; 97:45-50.-   [21] Jackwood D J, Sommer-Wagner S E. Molecular epidemiology of    infectious bursal disease viruses: Distribution and genetic analysis    of newly emerging viruses in the United States. Avian Dis 2005;    49:220-6.-   [22] Jackwood D J, Sommer S E, Knoblich H V. Amino Acid Comparison    of Infectious Bursal Disease Viruses Placed in the Same or Different    Molecular Groups by RT/PCR-RFLP. Avian Dis 2001; 45:330-9.-   [23] Kibenge F S B, Jackwood D J, Mercado C C. Nucleotide sequence    analysis of genome segment A of infectious bursal disease virus. J    Gen Virol 1990; 71:569-77.-   [24] Jackwood D J, Sommer-Wagner S E. Molecular studies on suspect    very virulent infectious bursal disease virus genomic RNA samples.    Avian Dis 2005; 49:246-51.-   [25] Dybing J K, Jackwood D J. Antigenic and immunogenic properties    of baculovirus-expressed infectious bursal disease viral proteins.    Avian Dis 1998; 42:80-91.-   [26] van den Berg T P, Eterradossi N, Toquin D, Meulemans G.    Infectious bursal disease (Gumboro Disease). World Trade and Public    Health Implications, OIE Scientific and Technical Rev 2000;    19:509-43.-   [27] Vakharia V N, Snyder D B, Lutticken D H, Mengel-Whereat S A,    Edwards G H, Goodwin M A. Active and passive protection against    variant and classic infectious bursal disease virus strains induced    by baculovirus-expressed structural proteins. Vaccine 1994;    12:452-6.-   [28] Vakharia V N, Snyder D B, He J, Edwards G H, Savage P K,    Mengel-Whereat S A. Infectious bursal disease virus structural    proteins expressed in a baculovirus recombinant confer protection in    chickens. J Gen Virol 1993; 74:1201-6.-   [29] Pitcovski J, Di-Castro D, Shaaltiel Y, et al. Insect    cell-derived VP2 of infectious bursal disease virus confers    protection against the disease in chickens. Avian Dis 1996;    40:753-61.-   [30] Martinez-Torrecuadrada J L, Lazaro B, Rodriguez J F, Casal J I.    Antigenic Properties and Diagnostic Potential of    Baculovirus-Expressed Infectious Bursal Disease Virus Proteins VPX    and VP3. Clin and Diag Lab Immunol 2000 Jul. 1; 7:645-51.-   [31] Martinez-Torrecuadrada J L, Saubi N, Pages-Mante′ A, Caston J    R, Espuna E, Casal J I. Structure-dependent efficacy of infectious    bursal disease virus (IBDV) recombinant vaccines. Vaccine 2003;    21:1952-60.-   [32] Coulibaly F, Chevalier C, Delmas B, Rey F A. Crystal Structure    of an Aquabirnavirus Particle: Insights into Antigenic Diversity and    Virulence Determinism. J Virol 2009; 84:1792-9.

SEQUENCES SEQ ID NO: 1 GTACCTGATCACCATGGCTGCATCAGAGTTC SEQ ID NO: 2CAGGATGATCACTCAAGGTCCTCATCAGAG SEQ ID NO: 3TTCGATGATCACGATGACAAACCTGTCAGATC SEQ ID NO: 4ACTACTGATCACCCCTTGTCGGCGGCGAGAG SEQ ID NO: 5 GCCCAGAGTCTACACCATSEQ ID NO: 6 CCCGGATTATGTCTTTGAVariant Virus pp34 VP3 Nucleotide Sequence SEQ ID NO: 7GTACCTGATCACCATGGCTGCATCAGAGTTCAAAGAGACCCCTGAACTCGAGAGCGCCGTCAGAGCCATGGAGGCAGCAGCCAATGTGGACCCACTGTTCCAATCTGCACTCAGTGTGTTCATGTGGCTGGAAGAGAATGGGATTGTGACTGACATGGCCAACTTCGCACTCAGCGACCCGAACGCCCATCGGATGCGAAATTTTCTTGCAAACGCACCACAAGCAGGCAGCAAGTCGCAAAGGGCCAAGTACGGGACAGCAGGCTACGGAGTGGAGGCCCGGGGCCCCACACCAGAGGAAGCACAGAGGGAAAAAGACACACGGATCTCAAAGAAGATGGAGACCATGGGCATCTACTTTGCGACACCGGAATGGGTAGCACTCAATGGGCACCGAGGGCCAAGCCCAGGCCAGCTAAAGTACTGGCAGAACACACGAGAAATACCGGACCCAAATGAGGACTATCTAGACTACGTGCATGCAGAGAAGAGCCGGTTGGCATCAGAAGAACAAATCCTAAGGGCAGCTACGTCGATCTACGGGGCTCCAGGACAGGCAGAGCCACCCCAAGCTTTCATAGATGAAGTTGCCAAAGTCTATGAAATCAACCATGGACGTGGCCCCAACCAAGAACAGATGAAAGATCTGCTCTTGACTGCGATGGAGATGAAGCATCGCAATCCCAGGCGGGCTCCACCAAAGCCCAAGCCAAAACCCAATGCTCCAACACAGAGACCCCCTGGTCGGCTGGGCCGCTGGATCAGGACTGTCTCTGATGAGGACCTTGAGTGATCATCCT GVariant Virus pp34 VP3 Amino Acid Sequence SEQ ID NO: 8MAASEFKETPELESAVRAMEAAANVDPLFQSALSVFMWLEENGIVTDMANFALSDPNAHRMRNFLANAPQAGSKSQRAKYGTAGYGVEARGPTPEEAQREKDTRISKKMETMGIYFATPEWVALNGHRGPSPGQLKYWQNTREIPDPNEDYLDYVHAEKSRLASEEQILRAATSIYGAPGQAEPPQAFIDEVAKVYEINHGRGPNQEQMKDLLLTAMEMKHRNPRRAPPKPKPKPNAPTQRPPGRLGRWI RTVSDEDLE*Variant Virus pp34 pVP2 Nucleotide Sequence SEQ ID NO: 9AACGATGATCACGATGACAAACCTGTCAGATCAAACCCAACAGATTGTTCCGTTCATACGGAGCCTTCTGATGCCAACAACCGGACCGGCGTCCATTCCGGACGACACCCTGGAGAAGCACACTCTCAGGTCAGAGACCTCGACCTACAATTTGACTGTGGGGGACACAGGGTCAGGGCTAATTGTCTTTTTCCCTGGCTTCCCTGGCTCAATTGTGGGTGCTCACTACACACTGCAGAGCAATGGGAACTACAAGTTCAATCAGATGCTCCTGACGGCACAGAACCTACCGGCCAGCTACAACTACTGCAGGCTAGTGAGTCGGAGTCTCACAGTAAGGTCAAGCACACTCCCTGGTGGCGTTTATGCACTAAACGGCACCATAAACGCCGTGACCTTCCAAGGAAGCCTGAGTGAACTGACAGATGTTAGCTACAATGGGTTGATGTCTGCAACAGCCAACATCAACGACAAAATCGGGAACGTCCTAGTAGGGGAAGGGGTCACCGTCCTCAGCTTACCCACATCATATGATCTTGGGTATGTGAGGCTTGGTGACCCCATACCCGCTATAGGGCTTGACCCAAAAATGGTAGCAACATGTGACAGCAGTGACAGGCCCAGAGTCTACACCATAACTGCAGCCGATAATTACCAATTCTCATCACAGTACCAAACAGGTGGGGTAACAATCACACTGTTCTCGGCCAACATTGATGCTATCACAAGTCTCAGCGTTGGGGGGGAGCTCGTGTTCAAAACAAGTGTCCAAAACCTTGTACTGGGCGCCACCATCTACCTTATAGGCTTTGATGGGACTGCGGTAATCACCAGAGCCGTGGCCGCAAACAATGGGCTGACGGCCGGTATCGACAATCTTATGCCATTCAATCTTGTGATTCCGACCAACGAGATAACCCAACCAATCACATCCATCAAACTGGAGATAGTGACCTCCAAAAGTGATGGTCAGGCAGGGGAACAGATGTCATGGTCGGCAAGTGGGAGCCTAGCAGTGACGATCCATGGTGGCAACCATCCAGGAGCCCTCCGTCCCGTCACACTAGTGGCCTACGAAAGAGTGGCAACAGGATCTGTCGTTACGGTCGCTGGGGTGAGCAACTTCGAGCTGATCCCAAATCCTGAACTAGCAAAGAACCTGGTTACAGAATACGGCCGATTTGACCCAGGAGCCATGAACTACACAAAATTAATACTGAGTGAGAGGGACCGCCTTGGCATCAAGACTGTCTGGCCAACAAGGGAGTACACTGACTTTCGTGAGTACTTCATGGAGGTGGCCGACCTCAACTCTCCCCTGAAGATTGCAGGAGCATTTGGCTTCAAAGACATAATCCGGGCCATAAGGAGGATAGCTGTGCCGGTGGTCTCTACACTGTTCCCACCTGCTGCTCCTCTGGCCCATGCAATTGGGGAAGGTGTAGACTACCTGCTGGGCGATGAGGCACAGGCTGCTTCAGGAACTGCTCGAGCCGCGTCAGGAAAAGCAAGGGCTGCCTCAGGCCGCATAAGGCAGCTGACTCTCGCCGCCGACAAGGGGTGATCAGTATGT Variant Virus pp34 pVP2 Amino Acid SequenceSEQ ID NO: 10 MTNLSDQTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFFPGFPGSIVGAHYTLQSNGNYKFNQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYALNGTINAVTFQGSLSELTDVSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLGYVRLGDPIPAIGLDPKMVATCDSSDRPRVYTITAADNYQFSSQYQTGGVTITLFSANIDAITSLSVGGELVFKTSVQNLVLGATIYLIGFDGTAVITRAVAANNGLTAGIDNLMPFNLVIPTNEITQPITSIKLEIVTSKSDGQAGEQMSWSASGSLAVTIHGGNHPGALRPVTLVAYERVATGSVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERDRLGIKTVWPTREYTDFREYFMEVADLNSPLKIAGAFGFKDIIRAIRRIAVPVVSTLFPPAAPLAHAIGEGVDYLLGDEAQAASGTARAASGKAR AASGRIRQLTLAADKG*Classic Virus Mo195 pVP2 Nucleotide Sequence SEQ ID NO: 11AACGATGATCACGATGACAAACCTGTCAGATCAAACCCAACAGATTGTTCCGTTCATACGGAGCCTTCTGATGCCAACAACCGGACCGGCGTCCATTCCGGACGACACCCTGGAGAAGCACACTCTCAGGTCAGAGACCTCGACTTACAATTTGACTGTGGGGGACACAGGGTCAGGGCTAATTGTCTTTTTCCCTGGATTCCCTGGCTCAATTGTGGGTGCTCACTACACACTGCAGAGCAATGGGAACTACAAGTTCGATCAGATGCTCCTGACTGCCCAGAACCTACCGGCCAGCTACAACTACTGCAGGCTAGTGAGTCGGAGTCTCACAGTAAGGTCAAGCACACTCCCTGGTGGCGTTTATGCACTAAACGGCACCATAAACGCCGTGACCTTCCAAGGAAGCCTGAGTGAGCTGACAGATGTTAGCTACAATGGGTTGATGTCTGCAACAGCCAACATCAACGACAAAATTGGGAACGTCCTAGTAGGGGAAGGAGTCACCGTCCTCAGCCTACCCACATCATATGATCTTGGGTATGTGAGGCTTGGTGACCCCATACCCGCTATAGGGCTTGACCCAAAAATGGTAGCAACATGTGACAGCAGTGACAGGCCCAGAGTCTACACCATAACTGCAGCTGATGATTACCAATTCTCATCACAGTACCAACCAGGTGGGGTAACAATCACACTGTTCTCAGCCAACATTGATGCCATCACAAGCCTCAGCGTCGGGGGAGAGCTCGTGTTCAAAACCAGCGTCCAAAGCCTTGTACTGGGCGCCACCATCTACCTCATAGGATTTGATGGGACTGCGGTAATCACCAGAGCTGTGGCCGCAAACAATGGGCTGACGGCCGGCATCGACAATCTTATGCCATTCAATCTTGTGATTCCAACCAACGAGATAACCCAGCCAATCACATCCATCAAATTGGAGATAGTTACCTCCAAAAGTAGTGGTCAGGAAGGGGATCAGATGTCATGGTCGGCAAGTGGGAGCCTAGCAGTGACGATCCATGGTGGCAACTATCCAGGGGCCCTCCGTCCCGTCACACTAGTAGCTTACGAAAGAGTGGCAACAGGATCTGTCGTTACGGTCGCTGGGGTGAGCAACTTCGAGCTGATCCCAAATCCTGAACTAGCAAAGAACCTGGTTACAGAATACGGCCGATTTGACCCAGGAGCCATGAACTACACAAAATTGATACTGAGTGAGAGGGACCGTCTTGGCATCAAGACCGTCTGGCCAACAAGGGAGTACACTGACTTTCGTGAGTACTTCATGGAGGTGGCCGACCTCAACTCTCCCCTGAAGATTGCAGGAGCATTTGGCTTCAAAGATATTATCCGGGCCATAAGGAGGATAGCTGTGCCGGTGGTCTCTACATTGTTCCCACCTGCTGCTCCCCTAGCCCATGCAATTGGGGAAGGTGTAGACTACCTGCTGGGCGATGAGGCACAGGCTGCTTCAGGAACTGCTCGAGCCGCGTCAGGAAAAGCAAGGGCTGCCTCAGGCCGCATAAGGCAGCTAACTCTCGCCGCCGACAAGGGGTGATCAGTATGT Classic Virus Mo195 pVP2 Amino Acid SequenceSEQ ID NO: 12 MTNLSDQTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFFPGFPGSIVGAHYTLQSNGNYKFDQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYALNGTINAVTFQGSLSELTDVSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLGYVRLGDPIPAIGLDPKMVATCDSSDRPRVYTITAADDYQFSSQYQPGGVTITLFSANIDAITSLSVGGELVFKTSVQSLVLGATIYLIGFDGTAVITRAVAANNGLTAGIDNLMPFNLVIPTNEITQPITSIKLEIVTSKSSGQEGDQMSWSASGSLAVTIHGGNYPGALRPVTLVAYERVATGSVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERDRLGIKTVWPTREYTDFREYFMEVADLNSPLKIAGAFGFKDIIRAIRRIAVPVVSTLFPPAAPLAHAIGEGVDYLLGDEAQAASGTARAASGKAR AASGRIRQLTLAADKG*Classic IBDV (FD181) VP3 Nucleotide Sequence SEQ ID NO: 13GTACCTGATCACCATGGCTGCATCAGAGTTCAAAGAGACCCCCGAACTCGAGAGTGCCGTCAGAGCAATGGAAGCAGCAGCCAACGTGGACCCACTATTCCAATCTGCACTCAGTGTGTTCATGTGGCTGGAAGAGAATGGGATTGTGACTGACATGGCCAACTTCGCACTCAGCGACCCGAACGCCCATCGGATGCGAAATTTTCTTGCAAACGCACCACAAGCAGGCAGCAAGTCGCAAAGGGCCAAGTACGGGACAGCAGGCTACGGAGTGGAGGCTCGGGGCCCCGCGCCAGAGGAAGCACAGAGGGAAAAAGACACACGGATCTCAAAGAAGATGGAGACCATGGGCATCTACTTTGCAACACCAGAATGGGTAGCACTCAATGGGCACCGAGGGCCAAGCCCCGGCCAGCTAAAGTACTGGCAGAGCACACGAGAAATACCGGACCCAAACGAGGACTATCTAGACTACGTGCATGCAGAGAAGAGCCGGTTGGCATCAGAAGAACAAATCCTAAGGGCAGCTACGTCGATCTACGGGGCTCCAGGACAGGCAGAGCCACCCCAAGCTTTCATAGACGAAGTTGCCAAAGTCTATGAAATCAACCATGGACGTGGCCCAAACCAAGAACAGATGAAAGATCTGCTCTTGACTGCGATGGAGATGAAGCATCGCAATCCCAGGCGGGCTCTACCAAAGCCCAAGCCAAAACCCAATGCTCCAACACAGAGACCCCCTGGTCGGCTGGGCCGCTGGATCAGGACCGTCTCTGATGAGGACCTTGAGTGATCATCCT GClassic IBDV (FD181) VP3 Amino Acid Sequence SEQ ID NO: 14MAASEFKETPELESAVRAMEAAANVDPLFQSALSVFMWLEENGIVTDMANFALSDPNAHRMRNFLANAPQAGSKSQRAKYGTAGYGVEARGPAPEEAQREKDTRISKKMETMGIYFATPEWVALNGHRGPSPGQLKYWQSTREIPDPNEDYLDYVHAEKSRLASEEQILRAATSIYGAPGQAEPPQAFIDEVAKVYEINHGRGPNQEQMKDLLLTAMEMKHRNPRRALPKPKPKPNAPTQRPPGRLGRWI RTVSDEDLE*vvIBDV (Isr4) VP3 Nucleotide Sequence SEQ ID NO: 15GTACCTGATCACCATGGCTGCATCAGAGTTCAAAGAGACCCCCGAACTCGAGAGTGCCGTCAGAGCAATGGAAGCAGCAGCCAACGTGGACCCACTATTCCAATCTGCACTCAGTGTGTTCATGTGGCTGGAAGAGAATGGGATTGTGACTGACATGGCCAACTTCGCACTCAGCGACCCGAACGCCCATCGGATGCGAAATTTTCTTGCAAACGCACCACAAGCAGGCAGCAAGTCGCAAAGGGCCAAGTACGGGACAGCAGGCTACGGAGTGGAGGCTCGGGGCCCCACACCAGAGGAAGCACAGAGGGAAAAAGACACACGGATCTCAAAGAAGATGGAGACCATGGGCATCTACTTTGCAACACCAGAATGGGTAGCACTCAATGGGCACCGAGGGCCAAGCCCCGGCCAGCTAAAGTACTGGCAGAACACACGAGAAATACCGGACCCAAACGAGGACTATCTAGACTACGTGCATGCAGAGAAGAGCCGGTTGGCATCAGAAGAACAAATCCTAAGGGCAGCTACGTCGATCTACGGGGCTCCAGGACAGGCAGAGCCACCCCAGGCTTTCATAGACGAAGTTGCCAAAGTCTATGAAATCAACCATGGACGTGGCCCAAACCAAGAACAGATGAAAGATCTGCTCTTGACTGCGATGGAGATGAAGCATCGCAATCCCAGGCGGGCTCTACCAAAGCCCAAGCCGAAACCCAATGCTCCAACACAGAGACCCCCTGGTCGGCTGGGCCGCTGGATCAGGACCGCCTCTGATGAGGACCTTGAGTGATCATCCT GvvIBDV (Isr4) VP3 Amino Acid Sequence SEQ ID NO: 16MAASEFKETPELESAVRAMEAAANVDPLFQSALSVFMWLEENGIVTDMANFALSDPNAHRMRNFLANAPQAGSKSQRAKYGTAGYGVEARGPTPEEAQREKDTRISKKMETMGIYFATPEWVALNGHRGPSPGQLKYWQNTREIPDPNEDYLDYVHAEKSRLASEEQILRAATSIYGAPGQAEPPQAFIDEVAKVYEINHGRGPNQEQMKDLLLTAMEMKHRNPRRALPKPKPKPNAPTQRPPGRLGRWI RTASDEDLE*Classic IBDV (FD181) pVP2 Nucleotide Sequence SEQ ID NO: 17AACGATGATCACGATGACAAACCTGTCAGATCAAACCCAACAGATTGTTCCGTTCATACGGAGCCTTCTGATGCCAACAACCGGACCGGCGTCCATTCCGGACGACACCCTGGAGAAGCACACTCTCAGGTCAGAGACCTCGACCTACAATTTGACTGTGGGGGACACAGGGTCAGGGCTAATTGTCTTTTTCCCTGGATTCCCTGGCTCAATTGTGGGTGCTCACTACACACTGCAGAGCAATGGGAACTACAAGTTCGATCAGATGCTCCTGACTGCCCAGAACCTACCGGCCAGTTACAACTACTGCAGGCTAGTGAGTCGGAGTCTCACAGTGAGGTCAAGCACACTTCCTGGTGGCGTTTATGCACTAAACGGCACCATAAACGCCGTGACCTTCCAAGGAAGCCTGAGTGAACTGACAGATGTTAGCTACAATGGGTTGATGTCTGCAACAGCCAACATCAACGACAAAATTGGGAACGTCCTAGTAGGGGAAGGGGTCACCGTCCTCAGCTTACCCACATCATATGATCTTGGGTATGTGAGGCTTGGTGACCCCATTCCCGCAATAGGGCTTGACCCAAAAATGGTAGCCACATGTGACAGCAGTGACAGGCCCAGAGTCTACACCATAACTGCAGCCGATGATTACCAATTCTCATCACAGTACCAACCAGGTGGGGTAACAATCACACTGTTCTCAGCCAACATTGATGCCATCACAAGCCTCAGCGTTGGGGGAGAGCTCGTGTTTCAAACAAGCGTCCACGGCCTTGTACTGGGCGCCACCATCTACCTCATAGGCTTTGATGGGACAGCGGTAATCACCAGGGCTGTGGCCGCAAACAATGAGCTGACGACCGGCACCGACAACCTTTTGCCATTCAATCTTGTGATTCCAACAAACGAGATAACCCAGCCAATCACATCCATCAAACTGGAGATAGTGACCTCCAAAAGTGGTGGTCAGGCAGGGGATCAGATGTCATGGTCCGCAAGAGGGAGCCTAGCAGTGACGATCCATGGTGGCAACTATCCAGGGGCCCTCCGTCCCGTCACGCTAGTGGCCTACGAAAGAGTGGCAACAGGATCCGTCGTTACGGTCGCTGGGGTGAGCAACTTCGAGCTGATCCCAAATCCTGAACTAGCAAAGAACCTGGTTACAGAATACGGCCGATTTGACCCAGGAGCCATGAACTACACAAAATTGATACTGAGTGAGAGGGACCGTCTTGGCATCAAGACCGTCTGGCCAACAAGGGAGTACACTGACTTTCGTGAATACTTCATGGAGGTGGCCGACCTCAACTCTCCCCTGAAGATTGCAGGAGCATTCGGCTTCAAAGACATAATCCGGGCCATAAGGAGGATAGCTGTGCCGGTGGTCTCCACATTGTTCCCACCTGCCGCTCCCCTAGCCCATGCAATTGGGGAAGGTGTAGACTACCTGCTGGGCGATGAGGCACAGGCTGCTTCAGGAACTGCTCGAGCCGCGTCAGGAAAAGCAAGAGCTGCCTCGGGCCGCATAAGGCAGCTGACTCTCGCCGCCGACAAGGGGTGATCAGTAGTA Classic IBDV (FD181) pVP2 Amino Acid SequenceSEQ ID NO: 18 MTNLSDQTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFFPGFPGSIVGAHYTLQSNGNYKFDQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYALNGTINAVTFQGSLSELTDVSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLGYVRLGDPIPAIGLDPKMVATCDSSDRPRVYTITAADDYQFSSQYQPGGVTITLFSANIDAITSLSVGGELVFQTSVHGLVLGATIYLIGFDGTAVITRAVAANNELTTGTDNLLPFNLVIPTNEITQPITSIKLEIVTSKSGGQAGDQMSWSARGSLAVTIHGGNYPGALRPVTLVAYERVATGSVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERDRLGIKTVWPTREYTDFREYFMEVADLNSPLKIAGAFGFKDIIRAIRRIAVPVVSTLFPPAAPLAHAIGEGVDYLLGDEAQAASGTARAASGKAR AASGRIRQLTLAADKG*Variant IBDV (T1) pVP2 Nucleotide Sequence SEQ ID NO: 19AACGATGATCACGATGACAAACCTGTCAGATCAAACCCAACAGATTGTTCCGTTCATACGGAGCCTTCTGATGCCAACAACCGGACCGGCGTCCATTCCGGACGACACCCTGGAGAAGCACACTCTCAGGTCAGAGACCTCGACCTACAATTTGACTGTGGGGGACACAGGGTCAGGGCTAATTGTCTTTTTCCCTGGATTCCCTGGCTCAATTGTGGGTGCTCACTACACACTGCAGAGCAATGGGAACTACAAGTTCGATCAGATGCTCCTGACTGCCCAGAACCTACCGGCCAGCTACAACTACTGCAGGCTAGTGAGTCGGAGTCTCACAGTAAGGTCAAGCACACTCCCTGGTGGCGTTTATGCACTAAACGGCACCATAAACGCCGTGACCTTCCAAGGAAGCCTGAGTGAACTGACAGATGTTAGCTACAATGGGTTGATGTCTGCAACAGCCAACATCAACGACAAAATTGGGAACGTTCTAGTAGGGGAAGGGGTAACAGTCCTCAGCTTACCCACATCATATGATCTTGGGTATGTGAGGCTTGGTGACCCCATACCTGCTATAGGACTTGACCCAAAAATGGTAGCTACATGTGACAGCAGTGACAGGCCCAGAGTCTACACCATAACTGCAGCTGATAATTACCAGTTCTCATCACAGTACCAAACAGGTGGGGTAACAATCACACTGTTCTCAGCCAACATTGATGCCATCACAAGTCTCAGCGTTGGGGGAGAGCTTGTGTTCAAAACAAGCGTCCAAAACCTTGTACTGGGTGCCACCATCTACCTTATAGGCTTTGATGGGACTGCGGTAATCACCAGAGCTGTGGCCGCAAACAATGGGCTGACGGCCGGCATCGACAATCTTATGCCATTCAACCTTGTGATTCCAACCAATGAGATAACCCAGCCAATCACATCCATCAAACTAGAGATAGTGACCTCCAAAAGCAATGGGCAGGCAGAGGATCAGATGTCNTGGTCGGCAAGTGGGAGCCTGGCAGTGACGATCCATGGTGGCAACTATCCAGGAGCCCTCCGTCCCGTCACACTGGTGGCCTACGAAAGAGTGGCAACAGGATCTGTCGTTACGGTCGCAGGGGTGAGCAACTTCGAGCTGATCCCAAATCCTGAACTGGCAAAGAACCTGGTTACAGAATACGGCCGATTTGACCCAGGAGCCATGAACTACACGAAATTGATACTGAGTGAGAGGGACCGTCTTGGCATCAAGACCGTCTGGCCAACAAGGGAGTACACTGACTTTCGTGAGTACTTCATGGAGGTGGCCGACCTCAACTCTCCCCTGAAGATTGCAGGAGCATTTGGATTCAAGGACATAATCCGGGCCATAAGGAGGATAGCTGTGCCGGTGGTCTCTACATTGTTCCCACCTGCCGCTCCTCTAGCCCATGCAATTGGGGAAGGTGTAGACTACCTGCTGGGCGATGAGGCACAGGCTGCTTCAGGAACTGCTCGAGCCGCGTCAGGAAAAGCAAGGGCTGCCTCAGGCCGCATAAGGCAGCTGACTCTCGCCGCCGACAAGGGGTGATCAGTAGT Variant IBDV (T1) pVP2 Amino Acid SequenceSEQ ID NO: 20 MTNLSDQTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFFPGFPGSIVGAHYTLQSNGNYKFDQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYALNGTINAVTFQGSLSELTDVSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLGYVRLGDPIPAIGLDPKMVATCDSSDRPRVYTITAADNYQFSSQYQTGGVTITLFSANIDAITSLSVGGELVFKTSVQNLVLGATIYLIGFDGTAVITRAVAANNGLTAGIDNLMPFNLVIPTNEITQPITSIKLEIVTSKSNGQAEDQMSWSASGSLAVTIHGGNYPGALRPVTLVAYERVATGSVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERDRLGIKTVWPTREYTDFREYFMEVADLNSPLKIAGAFGFKDIIRAIRRIAVPVVSTLFPPAAPLAHAIGEGVDYLLGDEAQAASGTARAASGKAR AASGRIRQLTLAADKG*vvIBDV (Pf33) pVP2 Nucleotide Sequence SEQ ID NO: 21AACGATGATCACGATGACAAACCTGTCAGATCAAACCCAACAGATTGTTCCGTTCATACGGAGCCTTCTGATGCCAACAACCGGACCGGCGTCCATTCCGGACGACACCCTAGAGAAGCACACTCTCAGGTCAGAGACCTCGACCTACAATTTGACTGTGGGGGACACAGGGTCAGGGCTAATTGTCTTTTTCCCTGGTTTCCCTGGCTCAATTGTGGGTGCTCACTACACACTGCAGAGCAATGGGAGCTACAAGTTCGATCAGATGCTCCTGACTGCCCAGAACCTACCGGCCAGCTACAACTACTGCAGGCTAGTGAGTCGGAGTCTCACAGTGAGGTCAAGCACACTCCCTGGTGGCGTTTATGCTCTAAATGGCACCATAAACGCCGTGACCTTCCAAGGAAGCCTGAGTGAACTGACAGATGTTAGCTACAATGGGTTGATGTCTGCAACAGCCAACATCAACGACAAAATCGGGAACGTCCTAGTAGGGGAAGGGGTAACAGTCCTCAGCTTACCTACATCATACGATCTTGGGTATGTGAGACTCGGTGACCCCATTCCCGCTATAGGGCTCGACCCAAAAATGGTAGCAACATGTGACAGCAGTGACAGACCCAGAGTCTACACCATAACTGCAGCCGATGATTACCAATTCTCATCACAGTACCAAGCAGGTGGGGTAACAATCACACTGTTCTCAGCTAATATCGATGCCATCACAAGCCTCAGCATCGGGGGGGAACTCGTGTTTCAAACAAGCGTCCAAGGCCTCATACTGGGTGCTACCATCTACCTTATAGGCTTTGATGGGACTGCGGTAATCACCAGAGCTGTGGCAGCAGACAATGGGCTAACGGCCGGCACTGACAACCTTATGCCATTCAACATTGTGATTCCAACCAGCGAGATAACCCAGCCAATCACATCCATCAAACTGGAGATAGTGACCTCCAAAAGTGGTGGTCAGGCGGGGGATCAGATGTCATGGTCCGCAAGTGGGAGCCTAGCAGTGACGATCCACGGTGGCAACTACCCAGGGGCCCTCCGTCCCGTCACACTAGTAGCCTATGAAAGAGTGGCAACAGGGTCTGTCGTTACGGTCGCTGGGGTGAGCAACTTCGAGCTGATCCCAAATCCTGAACTAGCAAAGAACCTGGTCACAGAATACGGCCGATTTGACCCAGGGGCTATGAACTACACAAAATTAATACTGAGTGAGAGGGACCGTCTTGGCATCAAGACCGTATGGCCAACGAGGGAGTACACTGACTTTCGCGAGTACTTCATGGAGGTGGCCGACCTCAACTCTCCCCTGAAGATTGCAGGAGCATTTGGCTTCAAAGACATAATTCGGGCTCTAAGGAGGATAGCTGTGCCGGTGGTCTCTACACTGTTCCCACCAGCCGCTCCCCTAGCCCATGCAATTGGGGAAGGTGTAGACTACCTGCTGGGCGATGAGGCACAGGCTGCTTCAGGAACTGCTCGAGCCGCGTCAGGAAAAGCAAGAGCTGCCTCAGGTCGCATAAGGCAGCTAACTCTCGCCGCCGACAAGGGGTGATCAGTAGTA vvIBDV (Pf33) pVP2 Amino Acid SequenceSEQ ID NO: 22 MTNLSDQTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFFPGFPGSIVGAHYTLQSNGSYKFDQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYALNGTINAVTFQGSLSELTDVSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLGYVRLGDPIPAIGLDPKMVATCDSSDRPRVYTITAADDYQFSSQYQAGGVTITLFSANIDAITSLSIGGELVFQTSVQGLILGATIYLIGFDGTAVITRAVAADNGLTAGTDNLMPFNIVIPTSEITQPITSIKLEIVTSKSGGQAGDQMSWSASGSLAVTIHGGNYPGALRPVTLVAYERVATGSVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERDRLGIKTVWPTREYTDFREYFMEVADLNSPLKIAGAFGFKDIIRALRRIAVPVVSTLFPPAAPLAHAIGEGVDYLLGDEAQAASGTARAASGKAR AASGRIRQLTLAADKG*Serotype 2 IBDV (OH) pVP2 Nucleotide Sequence SEQ ID NO: 23GGGAATTCACTAGTGATTTTCGATGATCACGATGACAAACCTGTCAGATCACACCCAACAGATTGTTCCGTTCATACGGAGCCTTCTGATGCCAACGACCGGACCGGCGTCCATCCCGGACGACACCCTGGAGAAGCACACACTCAGGTCCGAAACCTCGACCTACAACTTGACTGTCGGGGACACAGGGTCAGGACTAATTGTCTTTTTCCCTGGATTCCCTGGTTCAGTTGTAGGTGCTCACTACACACTGCAGAGCAGTGGGAGCTACCAGTTCGACCAGATGCTCCTGACAGCGCAGAACCTGCCTGCGAGCTACAACTATTGCAGACTAGTGAGCAGGAGCCTAACCGTGCGGTCAAGCACACTCCCTGGTGGCGTTTATGCTCTAAATGGGACCATAAACGCGGTGACCTTCCAAGGAAGCCTGAGTGAGTTGACTGACTACAGCTACAACGGGCTGATGTCAGCCACTGCAAACATCAACGACAAGATCGGGAATGTCCTTGTTGGGGAAGGGGTGACTGTCCTAAGTCTACCAACCTCATATGACCTCAGTTATGTGAGGCTTGGCGACCCCATCCCAGCAGCAGGACTTGACCCAAAGTTGATGGCCACGTGCGACAGTAGTGATAGACCCAGAGTCTACACAGTAACAGCCGCTGATGAGTACCAATTCTCGTCGCAACTCATCCCAAGTGGAGTGAAGACTACACTGTTCACCGCCAACATCGATGCTCTTACAAGCCTCAGTGTTGGTGGTGAGCTTATCTTCAGCCAAGTAACGATCCAAAGCATTGAAGTGGACGTCACCATTTACTTCATTGGGTTCGACGGGACAGAGGTCACAGTCAAAGCTGTTGCAACAGACTTTGGGCTGACAACTGGGACGAACAACCTTGTGCCATTCAACCTGGTGGTCCCAACAAGTGAGATCACCCAACCCATCACTTCCATGAAACTAGAGGTAGTCACCCATAAAAGAGGAGGCACTGCTGGCGATCCGATATCATGGACAGTGAGCGGGACACTAGCTGTGACAGTGCACGGAGGCAACTATCCTGGGGCTCTCCGTCCCGTCACCCTAGTGGCCTATGAGCGAGTGGCAGCAGGATCCGTCGTCACAGTTGCAGGGGTGAGCAACTTCGAGCTGATCCCAAACCCTGAGCTTGCCAAGAACCTAGTCACAGAATATGGCCGATTTGACCCCGGAGCGATGAACTACACCAAACTAATACTGAGTGAGAGAGATCGTCTAGGCATAAAGACTGTCTGGCCAACCAGGGAGTACACTGACTTTAGAGAGTACTTCATGGAAGTTGCCGATCTCAACTCACCCTTAAAGATTGCAGGTGCGTTTGGTTTTAAGGACATAATCCGAGCCATCCGGAAGATTGCGGTACCAGTGGTATCCACACTCTTCCCACCAGCTGCACCCCTAGCCCATGCAATCGGAGAAGGTGTGGATTACCTTCTGGGCGATGAGGCCCAGGCAGCCTCAGGGACGGCTCGAGCCGCGTCAGGAAAAGCCAGGGCTGCCTCAGGAAGAATAAGGCAGCTGACTCTCGCCGCCGACAAGGGGTSerotype 2 IBDV (OH) pVP2 Amino Acid Sequence SEQ ID NO: 24MTNLSDHTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFFPGFPGSVVGAHYTLQSSGSYQFDQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYALNGTINAVTFQGSLSELTDYSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLSYVRLGDPIPAAGLDPKLMATCDSSDRPRVYTVTAADEYQFSSQLIPSGVKTTLFTANIDALTSLSVGGELIFSQVTIQSIEVDVTIYFIGFDGTEVTVKAVATDFGLTTGTNNLVPFNLVVPTSEITQPITSMKLEVVTHKRGGTAGDPISWTVSGTLAVTVHGGNYPGALRPVTLVAYERVAAGSVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERDRLGIKTVWPTREYTDFREYFMEVADLNSPLKIAGAFGFKDIIRAIRKIAVPVVSTLFPPAAPLAHAIGEGVDYLLGDEAQAASGTARAASGKA RAASGRIRQLTLAADKG*IPNV-2 Genogroup 1, pVP2 VLP Nucleotide Sequence: SEQ ID NO: 25ATGAGCACATCCAAGGCAACCGCAACCTACTTGAGATCCATTATGCTTCCCGAGAATGGGCCAGCAAGCATTCCGGACGACATAACAGAGAGGCATATACTAAAACAAGAGACCTCGTCATACAACTTAGAGGTCTCCGAATCAGGAAGTGGGCTTCTTGTCTGCTTCCCTGGAGCTGCTGGATCCAGGGTCGGTGCCCACTACAGGTGGAATCCGAACCAGACGGCACTAGAATTCGACCAGTGGCTAGAGACGTCACAGGACCTAAAGAAGGCATTCAACTACGGGAGACTGATCTCACGGAAATACGACATCCAGAGCTCAACCCTTCCCGCTGGTCTGTATGCACTCAATGGAACCCTGAACGCTGCCACCTTCGAAGGAAGTCTGTCTGAAGTAGAGAGCCTAACCTACAACAGCTTGATGTCCCTAACAACAAACCCACAGGACAAGGTCAACAATCAACTAGTGACCAAAGGAATCACCGTCCTGAATCTACCAACTGGGTTTGACAAGCCATACGTCCGCCTAGAGGACGAGACGCCACAGGGCCCCCAGTCCATGAACGGAGCAAGGATGAGGTGCACAGCTGCCATCGCACCAAGGAGGTATGAAATCGACCTCCCATCCGAACGACTGCCGACCGTGGCCGCGACTGGGACCCCAACAACAATTTATGAGGGGAATGCTGACATCGTGAACTCCACAACAGTGACCGGGGACATAACATTCCAACTCGAGGCCGAACCTGCCAATGAGACACGGTTCGACTTCATTCTACAGTTCCTGGGGCTGGACAACGACGTCCCCGTGGTTACCGTGACAAGCTCCACGCTAGTCACAGTGGACAACTACAGGGGGGCGTCAGCCAAGTTCACCCAGTCAATCCCAACAGAAATGATCACCAAACCCATCACACGGGTCAAGCTGGCCTACCAGCTCAACCAGCAGACCGCAATCGCAAACGCAGCAACGCTCGGAGCCAAGGGGCCGGCATCAGTCTCATTCTCATCCGGGAACGGCAATGTGCCGGGGGTCCTAAGACCCATAACCCTAGTGGCGTACGAGAAGATGACCCCCCAGTCAATCCTGACCGTGGCTGGCGTATCCAACTATGAGCTGATCCCAAACCCAGACCTACTGAAGAACATGGTCACCAAGTATGGAAAGTATGACCCTGAGGGCCTCAACTATGCCAAGATGATCCTGTCCCACAGAGAGGAGGCTGGACATTAGIPNV-2 Genogroup 1, pVP2 VLP Amino Acid Sequence: SEQ ID NO: 26MSTSKATATYLRSIMLPENGPASIPDDITERHILKQETSSYNLEVSESGSGLLVCFPGAAGSRVGAHYRWNPNQTALEFDQWLETSQDLKKAFNYGRLISRKYDIQSSTLPAGLYALNGTLNAATFEGSLSEVESLTYNSLMSLTTNPQDKVNNQLVTKGITVLNLPTGFDKPYVRLEDETPQGPQSMNGARMRCTAAIAPRRYEIDLPSERLPTVAATGTPTTIYEGNADIVNSTTVTGDITFQLEAEPANETRFDFILQFLGLDNDVPVVTVTSSTLVTVDNYRGASAKFTQSIPTEMITKPITRVKLAYQLNQQTAIANAATLGAKGPASVSFSSGNGNVPGVLRPITLVAYEKMTPQSILTVAGVSNYELIPNPDLLKNMVTKYGKYDPEGLNYAK MILSHREEAGHIPNV-10 Genogroup 1, pVP2 VLP Nucleotide Sequence: SEQ ID NO: 27ATGAGCACATCCAAGGCAACCGCAACCTACTTGAGATCCATTATGCTTCCCGAGAGAGACCTCGTCATACAACTTAGAGGTCTCCGAATCAGGAAGTGGGCTTCTTGTCTGCTTCCCTGGAGCTCCTGGATCCAGGGTCGGTGCCCACTACAGGTGGAATCTGAACCAGACGGCACTAGAATTCGACCAGTGGCTAGAGACGTCACAGGACCTAAAGAAGGCATTCAATTACGGGAGACTGATCTCACGGAAATACGACATCCAGAGCTCAACCCTTCCCGCTGGTCTGTATGCACTCAATGGAACCCTGAACGCCGCCACCTTCGAAGGAAGTCTGTCTGAAGTAGAGAGCCTAACCTACAACAGCTTGATGTCCCTAACAACAAACCCACAGGACAAGGTCAACAATCAACTAGTGACCAAAGGAATCACCGTCCTGAATCTACCAACTGGGTTTGACAAGCCATACGTCCGCCTAGAGGACGAGACGCCACAGGGCCCCCAGTCCATGAACGGAGCAAGGATGAGGTGCACAGCTGCCATCGCACCAAGGAGGTATGAAATCGACCTCCCATCCGAACGACTGCCGACCGTGGCCGCGACTGGGACCCCAACAACAATTTATGAGGGGAATGCTGACATCGTGAACTCCACAACAGTGACCGGGGACATAACATTCCAACTCGAGGCCGAACCTGCCAATGAGACACGGTTCGACTTCATTCTACAGTTCCTGGGGCTGGACAACGACGTCCCCGTGGTTACCGTGACAAGCTCCACGCTAGTCACAGTGGACAACCACAGGGGGGCGTCAGCCAAGTTCACCCAGTCAATCCCAACAGAAATGATCACCAAACCCATCACACGGGTCAAGCTGGCCTACCAGCTCAACCAGCAGACCGCAATCGCAAACGCAGCAACGCTCGGAGCCAAGGGGCCTGCATCAGTCTCATTCTCATCCGGGAACGGCAATGTGCCGGGGGTCCTAAGACCCATAACCCTAGTGGCGTACGAGAAGATGACCCCCCAGTCAATCCTGACCGTGGCTGGCGTATCCAACTATGAGCTGATCCCAAACCCAGACCTACTGAAGAACATGGTCACCAAGTATGGAAAGTATGACCCTGAGGGCCTCAACTATGCCAAGATGATCCTGTCCCACATAGAGGAGGCTGGACATTAGIPNV-10 Genogroup 1, pVP2 VLP Amino Acid Sequence: SEQ ID NO: 28MSTSKATATYLRSIMLPENGPASIPDDITERHILKQETSSYNLEVSESGSGLLVCFPGAPGSRVGAHYRWNLNQTALEFDQWLETSQDLKKAFNYGRLISRKYDIQSSTLPAGLYALNGTLNAATFEGSLSEVESLTYNSLMSLTTNPQDKVNNQLVTKGITVLNLPTGFDKPYVRLEDETPQGPQSMNGARMRCTAAIAPRRYEIDLPSERLPTVAATGTPTTIYEGNADIVNSTTVTGDITFQLEAEPANETRFDFILQFLGLDNDVPVVTVTSSTLVTVDNHRGASAKFTQSIPTEMITKPITRVKLAYQLNQQTAIANAATLGAKGPASVSFSSGNGNVPGVLRPITLVAYEKMTPQSILTVAGVSNYELIPNPDLLKNMVTKYGKYDPEGLNYAK MILSHIEEAGHIPNV-10 VP3 VLP Nucleotide Sequence: SEQ ID NO: 29ATGGCCAGAGCAAAAGAAGTGAAGGACGCCGAAGTGTTCAAACTTCTGAAACTCATGTCATGGACAAGAAAGAATGACCTCACAGATCACATGTATGAGTGGTCAAAGGAGGACCCCGATGCAATCAAATTTGGCAGGCTCGTCAGCACCCCCCCAAAACACCAAGAGAAGCCAAAAGGACCTGACCAGCACACCGCCCAGGAGGCAAAGGCCACCAGGATCTCACTGGACGCCGTCAAAGCCGGCGCAGACTTTGCCTCCCCAGAGTGGATCGCGGAGAACAACTACCGCGGCCCAGCCCCAGGCCAGTTCAAGTACTACATGATAACGGGCAGAGTCCCAAACCCCGGAGAAGAGTACGAGGACTATGTGCGAAAACCGATAACTAGACCAACCGACATGGACAAAATCAGACGCCTAGCCAACAGTGTCTACGGCCTGCCCCACCAAGAACCCGCACCAGACGACTTCTACCAGGAAGTCGTCGAGGTGTTCGCAGAAAACGGGGGAAGAGGGCCCGACCAAGACCAAATGCAAGACCTGAGGGACTTGGCACGGCAGATGAAACGACGACCCCGACCAGCTGATACACGCAGGCAAACCAAGGCTCCACCCAGGGCGGCAACCTCCAGTGGATCACGGTTTACCCCCTCCGGCGATGACGGAGAAGTGTAA IPNV-10 VP3 VLP Amino Acid Sequence:SEQ ID NO: 30 MARAKEVKDAEVFKLLKLMSWTRKNDLTDHMYEWSKEDPDAIKFGRLVSTPPKHQEKPKGPDQHTAQEAKATRISLDAVKAGADFASPEWIAENNYRGPAPGQFKYYMITGRVPNPGEEYEDYVRKPITRPTDMDKIRRLANSVYGLPHQEPAPDDFYQEVVEVFAENGGRGPDQDQMQDLRDLARQMKRRPRPADTRRQTKAPPRAATSSGSRFTPSGDDGEV

What is claimed is:
 1. A polyvalent VP2 trimer of infectious pancreaticnecrosis virus (IPNV), wherein the polyvalent VP2 trimer comprises threeVP2 monomers, and wherein at least one of the VP2 monomers is from adifferent strain of IPNV than the other monomers, and wherein the VP2monomers are each independently from an IPNV strain selected from thegroup consisting of IPNV2, IPNV10, Te, C1, Ab, He, C2, C3, SP, YTAV, WB,and Jasper.
 2. The polyvalent VP2 of claim 1, wherein at least one ofthe VP2 monomers is from IPNV2 and at least one of the VP2 monomers isfrom IPNV10.
 3. A virus like particle (VLP) comprising VP3 proteins fromat least one strain of infectious pancreatic necrosis virus (IPNV) andthe polyvalent VP2 trimer of claim
 1. 4. The VLP of claim 3, wherein atleast one of the VP2 monomers is from IPNV2.
 5. The VLP of claim 3,wherein at least one of the VP2 monomers is from IPNV10.
 6. The VLP ofclaim 3, wherein at least one of the VP2 monomers is from IPNV2 and atleast one of the VP2 monomers is from IPNV10.
 7. The VLP of claim 3,comprising two VP2 monomers from IPNV2 and one VP2 monomer from IPNV10.8. The VLP of claim 3, comprising one VP2 monomer from IPNV2 and two VP2monomers from IPNV10.
 9. The VLP of claim 3, wherein the VP3 proteinsare from IPNV10.
 10. The VLP of claim 3, wherein the VP3 proteins arefrom more than one IPNV strain.
 11. A composition comprising the VLP ofclaim 3, and a pharmaceutically acceptable carrier.
 12. An isolated hostcell expressing the VLP of claim
 3. 13. The cell of claim 12, whereinthe cell is an insect cell.
 14. The cell of claim 13, wherein the insectcell is a Sf9 cell.
 15. A method of eliciting an immune response againstIPNV in a subject comprising administering to the subject a compositioncomprising the VLP of claim
 3. 16. The method of claim 15, wherein thesubject is a fish.
 17. The method of claim 16, wherein the fish aresalmonids.
 18. The method of claim 15, further comprising administeringto the subject a virulent IPNV to monitor the immune response.
 19. Themethod of claim 15, wherein the composition is administered in a singledose.